

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/SE05/000411

International filing date: 21 March 2005 (21.03.2005)

Document type: Certified copy of priority document

Document details: Country/Office: SE  
Number: 0400718-3  
Filing date: 22 March 2004 (22.03.2004)

Date of receipt at the International Bureau: 08 April 2005 (08.04.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

# PRV

PATENT- OCH REGISTRERINGSVERKET  
Patentavdelningen

PCT / SE 2005 / 0 0 0 4 1 1

2 1 -03- 2005

## Intyg Certificate

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

Ansökan ingavs ursprungligen på engelska.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.

The application was originally filed in English.

(71) Sökande                      AstraZeneca AB, Södertälje SE  
Applicant (s)

(21) Patentansökningsnummer    0400718-3  
Patent application number

(86) Ingivningsdatum                      2004-03-22  
Date of filing

Stockholm, 2005-01-27

För Patent- och registreringsverket  
For the Patent- and Registration Office



Hjordis Segerlund

Avgift  
Fee                      170:-

PATENT- OCH  
REGISTRERINGSVERKET  
SWEDEN

Postadress/Adress  
Box 5055  
S-102 42 STOCKHOLM

Telefon/Phone  
+46 8 782 25 00  
Vx 08-782 25 00

Telex  
17978  
PATOREG S

Telefax  
+46 8 666 02 86  
08-666 02 86

The present invention relates to certain compounds of formula I, to processes for preparing such compounds, to their use in the treatment of obesity, psychiatric and neurological disorders, and to pharmaceutical compositions containing them.


Melanin concentrating hormone (MCH) is a cyclic peptide that was first isolated from fish over 15 years ago. In mammals, MCH gene expression is localised to the ventral aspect of the zona inserta and the lateral hypothalamic area (Breton et al., *Molecular and Cellular Neurosciences*, vol. 4, 271-284 (1993)). The latter region of the brain is associated with the control of behaviours such as eating and drinking, with arousal and with motor activity (Baker, B., *Trends Endocrinol. Metab.* 5: 120-126(1994), vol. 5, No. 3, 120-126 (1994)). Although the biological activity in mammals has not been fully defined, recent work has indicated that MCH promotes eating and weight gain (US 5,849,708). Thus, MCH and its agonists have been proposed as treatments for anorexia nervosa and weight loss due to AIDS, renal disease, or chemotherapy. Similarly, antagonists of MCH can be used as a treatment for obesity and other disorders characterised by compulsive eating and excessive body weight. MCH projections are found throughout the brain, including the spinal cord, an area important in processing nociception, indicates that agents acting through MCH1r, such as compounds of formula I, will be useful in treating pain.

Two receptors for MCH (MCH1r (Shimomura et al. *Biochem Biophys Res Commun* 1999 Aug 11;261(3):622-6) & MCH2r (Hilol et al. *J Biol Chem.* 2001 Jun 8;276(23):20125-9)) have been identified in humans, while only one (MCH1r) is present in rodent species (Tan et al. *Genomics* 2002 Jun;79(6):785-92). In mice lacking MCH1r, there is no increased feeding response to MCH, and a lean phenotype is seen, suggesting that this receptor is responsible for mediating the feeding effect of MCH (Marsh et al. *Proc. Natl. Acad. Sci.*


USA, 2002 Mar 5;99(5):3240-5). In addition, MCH receptor antagonists have been demonstrated to block the feeding effects of MCH (Takekawa et al. *Eur. J. Pharmacol.* 2002 Mar 8;438(3):129-35), and to reduce body weight & adiposity in diet-induced obese rats (Borowsky et al. *Nature Med.* 2002 Aug;8(8):825-30). The conservation of distribution and sequence of MCH1r suggest a similar role for this receptor in man and rodent species. Hence, MCH receptor antagonists have been proposed as a treatment for obesity and other disorders characterised by excessive eating and body weight.

WO 03/106452 discloses certain 1-substituted-4-(substituted amino)piperidines which are alleged to be MCH-1r antagonists.

An abstract (No. 343 Vu V. Ma et al.,) from the 224<sup>th</sup> ACS meeting in Boston, MA, USA presents an MCH receptor antagonist for the potential treatment of obesity, with the following structure:



WO 01/14333 and GB 2 373 186 disclose that compounds of the following formula:



wherein

Z is  $CR^4R^5$ ,  $C(O)$  or  $CR^4R^5-Z^1$ ;

$Z^1$  is  $C_{1-4}$  alkylene (such as  $CH_2$ ),  $C_{2-4}$  alkenylene (such as  $CH=CH$ ) or  $C(O)NH$ ;

$R^1$  represents a  $C_1$ - $C_{12}$  alkyl group optionally substituted by one or more substituents independently selected from cyano, hydroxyl,  $C_1$ - $C_6$  alkoxy (such as methoxy or ethoxy),

$C_1$ - $C_6$  alkylthio (such as methylthio),  $C_{3-7}$  cycloalkyl (such as cyclopropyl),  $C_1$ - $C_6$  alkoxy carbonyl (such as methoxycarbonyl) and phenyl (itself optionally substituted by one or more of halogen, nitro, cyano,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  haloalkyl (such as  $CF_3$ ), phenyl( $C_1$ - $C_6$

alkyl) (such as benzyl), C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>6</sub> haloalkoxy, S(O)<sub>2</sub>(C<sub>1</sub>-C<sub>6</sub> alkyl), C(O)NH<sub>2</sub>, carboxy or C<sub>1</sub>-C<sub>6</sub> alkoxycarbonyl); or

R<sup>1</sup> represents C<sub>2</sub>-C<sub>6</sub> alkenyl optionally substituted by phenyl (itself optionally substituted by one or more of halogen, nitro, cyano, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl, phenyl(C<sub>1</sub>-C<sub>6</sub> alkyl), C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>6</sub> haloalkoxy, S(O)<sub>2</sub>(C<sub>1</sub>-C<sub>6</sub> alkyl), C(O)NH<sub>2</sub>, carboxy or C<sub>1</sub>-C<sub>6</sub> alkoxycarbonyl); or

R<sup>1</sup> represents a 3- to 14-membered saturated or unsaturated ring system which optionally comprises up to two ring carbon atoms that form carbonyl groups and which optionally further comprises up to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulphur, wherein the ring system is optionally substituted by one or more substituents independently selected from: halogen, cyano, nitro, oxo, hydroxyl, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> hydroxyalkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy(C<sub>1</sub>-C<sub>6</sub> alkyl), C<sub>3</sub>-C<sub>7</sub> cycloalkyl(C<sub>1</sub>-C<sub>6</sub> alkyl), C<sub>1</sub>-C<sub>6</sub> alkylthio(C<sub>1</sub>-C<sub>6</sub> alkyl), C<sub>1</sub>-C<sub>6</sub> alkylcarbonyloxy(C<sub>1</sub>-C<sub>6</sub> alkyl), C<sub>1</sub>-C<sub>6</sub> alkylS(O)<sub>2</sub>(C<sub>1</sub>-C<sub>6</sub> alkyl), aryl(C<sub>1</sub>-C<sub>6</sub> alkyl), heterocyclyl(C<sub>1</sub>-C<sub>6</sub> alkyl), arylS(O)<sub>2</sub>(C<sub>1</sub>-C<sub>6</sub> alkyl), heterocyclylS(O)<sub>2</sub>(C<sub>1</sub>-C<sub>6</sub> alkyl), aryl(C<sub>1</sub>-C<sub>6</sub> alkyl)S(O)<sub>2</sub>, heterocyclyl(C<sub>1</sub>-C<sub>6</sub> alkyl)S(O)<sub>2</sub>, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, carboxy-substituted C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>6</sub> haloalkoxy, C<sub>1</sub>-C<sub>6</sub> hydroxyalkoxy, C<sub>1</sub>-C<sub>6</sub> alkylcarboxy-substituted C<sub>1</sub>-C<sub>6</sub> alkoxy, aryloxy, heterocyclioxy, C<sub>1</sub>-C<sub>6</sub> alkylthio, C<sub>3</sub>-C<sub>7</sub> cycloalkyl(C<sub>1</sub>-C<sub>6</sub> alkylthio), C<sub>3</sub>-C<sub>6</sub> alkynylthio, C<sub>1</sub>-C<sub>6</sub> alkylcarbonylamino, C<sub>1</sub>-C<sub>6</sub> haloalkylcarbonylamino, SO<sub>3</sub>H, -NR<sup>7</sup>R<sup>8</sup>, -C(O)NR<sup>23</sup>R<sup>24</sup>, S(O)<sub>2</sub>NR<sup>18</sup>R<sup>19</sup>, S(O)<sub>2</sub>R<sup>20</sup>, R<sup>25</sup>C(O), carboxyl, C<sub>1</sub>-C<sub>6</sub> alkoxycarbonyl, aryl and heterocyclyl; wherein the foregoing aryl and heterocyclyl moieties are optionally substituted by one or more of halogen, oxo, hydroxy, nitro, cyano, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl, phenyl(C<sub>1</sub>-C<sub>6</sub> alkyl), C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>6</sub> haloalkoxy, S(O)<sub>2</sub>(C<sub>1</sub>-C<sub>6</sub> alkyl), C(O)NH<sub>2</sub>, carboxy or C<sub>1</sub>-C<sub>6</sub> alkoxycarbonyl;

m is 0 or 1;

Q represents an oxygen or sulphur atom or a group NR<sup>9</sup>, C(O), C(O)NR<sup>9</sup>, NR<sup>9</sup>C(O) or CH=CH;

n is 0, 1, 2, 3, 4, 5 or 6 provided that when n is 0, then m is 0;

each R<sup>2</sup> and R<sup>3</sup> independently represents a hydrogen atom or a C<sub>1</sub>-C<sub>4</sub> alkyl group, or (CR<sup>2</sup>R<sup>3</sup>)<sub>n</sub> represents C<sub>3</sub>-C<sub>7</sub> cycloalkyl optionally substituted by C<sub>1</sub>-C<sub>4</sub> alkyl;

T represents a group NR<sup>10</sup>, C(O)NR<sup>10</sup>, NR<sup>11</sup>C(O)NR<sup>10</sup> or C(O)NR<sup>10</sup>NR<sup>11</sup>;

$X^1$ ,  $X^2$ ,  $X^3$  and  $X^4$  are, independently,  $CH_2$ ,  $CHR^{12}$  {wherein each  $R^{12}$  is, independently,  $C_1$ - $C_4$  alkyl or  $C_3$ - $C_7$  cycloalkyl( $C_1$ - $C_4$  alkyl)} or  $C=O$ ; or, when they are  $CHR^{12}$ , the  $R^{12}$  groups of  $X^1$  and  $X^3$  or  $X^4$ , or,  $X^2$  and  $X^3$  or  $X^4$  join to form a two or three atom chain which is  $CH_2CH_2$ ,  $CH_2CH_2CH_2$ ,  $CH_2OCH_2$  or  $CH_2SCH_2$ ; provided always that at least two of  $X^1$ ,  $X^2$ ,  $X^3$  and  $X^4$  are  $CH_2$ ;

$R^4$  and  $R^5$  each independently represent a hydrogen atom or a  $C_1$ - $C_4$  alkyl group;

$R^6$  is aryl or heterocyclyl, both optionally substituted by one or more of: halogen, cyano, nitro, oxo, hydroxyl,  $C_1$ - $C_8$  alkyl,  $C_1$ - $C_6$  hydroxyalkyl,  $C_1$ - $C_6$  haloalkyl,  $C_1$ - $C_6$  alkoxy( $C_1$ - $C_6$  alkyl),  $C_3$ - $C_7$  cycloalkyl( $C_1$ - $C_6$  alkyl),  $C_1$ - $C_6$  alkylthio( $C_1$ - $C_6$  alkyl),  $C_1$ - $C_6$  alkylcarbonyloxy( $C_1$ - $C_6$  alkyl),  $C_1$ - $C_6$  alkyl $S(O)_2$ ( $C_1$ - $C_6$  alkyl), aryl( $C_1$ - $C_6$  alkyl), heterocyclyl( $C_1$ - $C_6$  alkyl), aryl $S(O)_2$ ( $C_1$ - $C_6$  alkyl), heterocyclyl $S(O)_2$ ( $C_1$ - $C_6$  alkyl), aryl( $C_1$ - $C_6$  alkyl) $S(O)_2$ , heterocyclyl( $C_1$ - $C_6$  alkyl) $S(O)_2$ ,  $C_2$ - $C_6$  alkenyl,  $C_1$ - $C_6$  alkoxy, carboxy-substituted  $C_1$ - $C_6$  alkoxy,  $C_1$ - $C_6$  haloalkoxy,  $C_1$ - $C_6$  hydroxyalkoxy,  $C_1$ - $C_6$  alkylcarboxy-substituted  $C_1$ - $C_6$  alkoxy, aryloxy, heterocyclioxy,  $C_1$ - $C_6$  alkylthio,  $C_3$ - $C_7$  cycloalkyl( $C_1$ - $C_6$  alkylthio),  $C_3$ - $C_6$  alkynylthio,  $C_1$ - $C_6$  alkylcarbonylamino,  $C_1$ - $C_6$  haloalkylcarbonylamino,  $SO_3H$ ,  $-NR^{16}R^{17}$ ,  $-C(O)NR^{21}R^{22}$ ,  $S(O)_2NR^{13}R^{14}$ ,  $S(O)_2R^{15}$ ,  $R^{26}C(O)$ , carboxyl,  $C_1$ - $C_6$  alkoxy-carbonyl, aryl and heterocyclyl; wherein the foregoing aryl and heterocyclyl moieties are optionally substituted by one or more of halogen, nitro, cyano,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  haloalkyl, phenyl( $C_1$ - $C_6$  alkyl),  $C_1$ - $C_6$  alkoxy,  $C_1$ - $C_6$  haloalkoxy,  $S(O)_2$ ( $C_1$ - $C_6$  alkyl),  $C(O)NH_2$ , carboxy or  $C_1$ - $C_6$  alkoxy-carbonyl;

$R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{21}$ ,  $R^{22}$ ,  $R^{23}$  and  $R^{24}$  are, independently hydrogen,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  haloalkyl,  $C_1$ - $C_6$  hydroxyalkyl,  $C_3$ - $C_7$  cycloalkyl,  $C_3$ - $C_7$  cycloalkyl( $C_1$ - $C_4$  alkyl) or phenyl( $C_1$ - $C_6$  alkyl); and,

$R^{15}$  and  $R^{20}$  are, independently,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  hydroxyalkyl,  $C_3$ - $C_6$  cycloalkyl,  $C_3$ - $C_7$  cycloalkyl( $C_1$ - $C_4$  alkyl) or  $C_1$ - $C_6$  alkyl optionally substituted by phenyl;

$R^{25}$  and  $R^{26}$  are, independently,  $C_1$ - $C_6$  alkyl or phenyl (optionally substituted by one or more of halogen, nitro, cyano,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  haloalkyl, phenyl( $C_1$ - $C_6$  alkyl),  $C_1$ - $C_6$  alkoxy,  $C_1$ - $C_6$  haloalkoxy,  $S(O)_2$ ( $C_1$ - $C_6$  alkyl),  $C(O)NH_2$ , carboxy or  $C_1$ - $C_6$  alkoxy-carbonyl);

or a pharmaceutically acceptable salt thereof, or solvate thereof, or a solvate of a salt thereof;

provided that when T is C(O)NR<sup>10</sup> and R<sup>1</sup> is optionally substituted phenyl then n is not 0, have activity as modulators of chemokine receptor activity.

Compound 2-(4-chlorophenoxy)-N-{1-[4-(1,2,3-thiadiazol-4-yl)benzyl]piperidin-4-yl}-acetamide is specially disclosed. Hence, all compounds disclosed in these applications as  
5 examples are disclaimed from the compound claims of the present invention.

There is an unmet need for MCH receptor antagonists that are more potent, more selective, more bioavailable and produce less side effects than known compounds in this field.

10 Summary of the invention

It is an object of the present invention to provide compounds, which are useful in treating obesity and related disorders, psychiatric disorders, neurological disorders and pain. This object has been reached in that a compound of formula I have been provided for use as a  
15 MCH receptor antagonist.

According to another aspect of the invention a pharmaceutical formulation is provided comprising a compound of formula I, and a pharmaceutically acceptable adjuvant, diluent or carrier.

20

According to a further aspect of the invention, the use of a compound of formula I is provided, in the preparation of a medicament for the treatment or prophylaxis of conditions associated with obesity.

25

According to yet another aspect of the invention, a method is provided of treating obesity, psychiatric disorders, anxiety, anxio-depressive disorders, depression, bipolar disorder, ADHD, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders and pain related disorders, comprising administering a pharmacologically effective amount of a compound of Formula I to a patient in need  
30 thereof.


30

According to another aspect of the invention, a process for the preparation of compounds of formula I is provided.

According to a further aspect of the invention, a method is provided of treating obesity, type II diabetes, Metabolic syndrome and prevention of type II diabetes comprising administering a pharmacologically effective amount of a compound of formula I to a patient in need thereof.

### Description of the invention

The invention relates to compounds of the general formula (I)



wherein X represents a 5-10 membered aryl or heteroaryl ring, such as phenyl or naphthyl, or a heterocyclic group selected from pyrrolyl, imidazolyl, furyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrazolyl, oxazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinolinyl, isoquinolyl, quinazolyl, indolyl, benzofuranyl, benzo[b]thienyl, benzimidazolyl,

wherein each X is optionally substituted by one or more of the following: cyano, halo, a  $\text{C}_{1-4}$  alkyl group optionally substituted by one or more fluoro, a  $\text{C}_{1-4}$  alkoxy group optionally substituted by one or more fluoro, a group  $\text{CONR}^a\text{R}^b$  in which  $\text{R}^a$  and  $\text{R}^b$  independently represent a  $\text{C}_{1-3}$  alkyl group, phenyl, phenoxy, 2-pyridyl or 3-pyridyl, wherein the aromatic substituents (i.e. phenyl, phenoxy, 2-pyridyl or 3-pyridyl) may optionally be substituted by fluoro, chloro or cyano,

Y can be  $\text{OCH}_2$ ,  $\text{SCH}_2$  (both in which the heteroatom is connected to X),  $\text{CH}_2\text{CH}_2$  or  $\text{CH=CH}$ , wherein each carbon in Y can be substituted by 1-2 methyl groups and/or 1-2 fluoride,

$\text{R}^1$  represents H or a  $\text{C}_{1-4}$  alkyl group,



Z represents phenyl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, isoxazolyl wherein each Z is optionally substituted by one or more of the following: cyano, halo, a C<sub>1-4</sub> alkyl group optionally substituted by one or more fluoro, a C<sub>1-4</sub> alkoxy group optionally substituted by one or more fluoro,

W represents phenyl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, isoxazolyl wherein each W is optionally substituted by one or more of the following: cyano, halo, a C<sub>1-4</sub> alkyl group optionally substituted by one or more fluoro, a C<sub>1-4</sub> alkoxy group optionally substituted by one or more fluoro,

as well as tautomers, optical isomers and racemates thereof as well as pharmaceutically acceptable salts, thereof,

with the proviso that 2-(4-chlorophenoxy)-N-{1-[4-(1,2,3-thiadiazol-4-yl)benzyl]piperidin-4-yl}acetamide is excluded.

Particular groups now follow in which some of X, Y, Z, W, and R<sup>1</sup> in compounds of formula I are further defined. It will be understood that such group definitions may be used where appropriate with any of the other group definitions, claims or embodiments defined hereinbefore or hereinafter.

In a particular group of compounds of formula I, X represents a phenyl or pyridyl group substituted with one or more cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl,

Y is OCH<sub>2</sub> or SCH<sub>2</sub> (both in which the heteroatom is connected to X) CH<sub>2</sub>CH<sub>2</sub> or CH=CH,

R<sup>1</sup> is hydrogen or methyl,

Z is phenyl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrrolyl wherein each Z is optionally substituted by cyano, fluoro, chloro or trifluoromethyl,

W represents phenyl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, isoxazolyl wherein each W is optionally substituted by one or more of the following: cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl,

as well as pharmaceutically acceptable salts thereof.

In another particular group of compounds of formula I, X represents naphthyl or a heteroaryl ring selected from quinolinyl, isoquinolyl, quinazolyl, indolyl, benzofuranyl, benzo[*b*]thienyl, or benzimidazolyl,

wherein each X is optionally substituted by one or more of the following: cyano, halo, a C<sub>1-4</sub> alkyl group optionally substituted by one or more fluoro, a C<sub>1-4</sub> alkoxy group optionally substituted by one or more fluoro, a group CONR<sup>a</sup>R<sup>b</sup> in which R<sup>a</sup> and R<sup>b</sup> independently represent a C<sub>1-3</sub> alkyl group,

Y is OCH<sub>2</sub> or SCH<sub>2</sub> (both in which the heteroatom is connected to X) CH<sub>2</sub>CH<sub>2</sub> or CH=CH, R<sup>1</sup> is hydrogen or methyl,

Z is phenyl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrrolyl wherein each Z is optionally substituted by cyano, fluoro, chloro or trifluoromethyl,

W represents phenyl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, isoxazolyl wherein each W is optionally substituted by one or more of the following: cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl,

as well as pharmaceutically acceptable salts thereof.

In yet another group of compounds of formula I, X represents a phenyl or pyridyl group optionally substituted by one or more halogen and substituted by a phenyl, phenoxy, 2-pyridyl or 3-pyridyl group, wherein the substituents (i.e. phenyl, phenoxy, 2-pyridyl or 3-pyridyl) may optionally be further substituted by one or more fluoro, chloro or cyano,

Y is OCH<sub>2</sub> or SCH<sub>2</sub> (both in which the heteroatom is connected to X) CH<sub>2</sub>CH<sub>2</sub> or CH=CH, R<sup>1</sup> is hydrogen or methyl,

Z is phenyl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrrolyl wherein each Z is optionally substituted by cyano, fluoro, chloro or trifluoromethyl,

W represents phenyl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, isoxazolyl wherein each W is optionally substituted by

one or more of the following: cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl,

as well as pharmaceutically acceptable salts thereof.

- 5 In a further particular group of compounds of formula I, X represents a phenyl group substituted with one or more cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl,

Y is preferably  $\text{OCH}_2$  (in which the heteroatom is connected to X),

$\text{R}^1$  is hydrogen,

- 10 Z is thienyl, furyl or pyrrolyl,

W represents phenyl or a heterocyclic group selected from pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, isoxazolyl wherein each W is optionally substituted by one or more of the following: cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl,

- 15 as well as pharmaceutically acceptable salts thereof.

In another particular group of compounds of formula I, X represents a phenyl group substituted with one or more cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl,

- 20 Y is  $\text{OCH}_2$  (in which the heteroatom is connected to X),

$\text{R}^1$  is hydrogen,

Z is 2,5-thienyl (where position 1 is linked to group W),

W represents phenyl or a heterocyclic group selected from pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, isoxazolyl wherein each W is optionally substituted by one or more of the following: cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl,  
as well as pharmaceutically acceptable salts thereof.

- 25  
30 In a further particular group of compounds of formula I, X represents a phenyl group substituted with one or more cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl,

Y is  $\text{OCH}_2$  (in which the heteroatom is connected to X),

R<sup>1</sup> is hydrogen,

Z is 2,5-furyl (where position 1 is linked to group W),

W represents phenyl or a heterocyclic group selected from pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, isoxazolyl wherein each W is optionally substituted by one or more of the following: cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl, as well as pharmaceutically acceptable salts thereof.

In another particular group of compounds of formula I, X represents a phenyl group substituted with one or more cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl,

Y is OCH<sub>2</sub>

R<sup>1</sup> is hydrogen,

Z is 1,3-1H pyrrolyl (in which the heteroatom is connected to W).

W represents phenyl or a heterocyclic group selected from pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, isoxazolyl wherein each W is optionally substituted by one or more of the following: cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl, as well as pharmaceutically acceptable salts thereof.

In one group of compounds of formula I, Z is pyrrolyl and in another group of compounds, Z is 1,3-1H pyrrolyl (in which the heteroatom is connected to W).

In yet another group of compounds of formula I, Y is OCH<sub>2</sub>.

In a further group of compounds of Formula I, W is phenyl or 2-pyridyl, optionally substituted by one or more of the following: cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl.

The term "pharmaceutically acceptable salt" refers to pharmaceutically acceptable acid addition salts. A suitable pharmaceutically acceptable salt of a compound of Formula I is,

for example, an acid-addition salt of a compound of Formula I which is sufficiently basic, for example an acid-addition salt with an inorganic or organic acid such as:

(1S)-(+)-10-camphorsulfonic acid; cyclohexylsulfamic acid; phosphoric acid; dimethylphosphoric acid; p-toluenesulfonic acid; L-lysine; L-lysine hydrochloride; 5 saccharinic acid; methanesulfonic acid; hydrobromic acid; hydrochloric acid; sulphuric acid; 1,2-ethanedisulfonic acid; (+/-)-camphorsulfonic acid; ethanesulfonic acid; nitric acid; p-xylenesulfonic acid; 2-mesitylenesulfonic acid; 1,5-naphthalenedisulfonic acid; 1-naphthalenesulfonic acid; 2-naphthalenesulfonic acid; benzenesulfonic acid; maleic acid; D-glutamic acid; L-glutamic acid; D,L-glutamic acid; L-arginine; glycine; salicylic acid; 10 tartaric acid; fumaric acid; citric acid; L-(-)-malic acid; D,L-malic acid and D-gluconic acid.

Throughout the specification and the appended claims, a given chemical formula or name shall encompass all tautomers, all stereo and optical isomers and racemates thereof as well 15 as mixtures in different proportions of the separate enantiomers, where such isomers and enantiomers exist, as well as pharmaceutically acceptable salts thereof. Isomers may be separated using conventional techniques, e.g. chromatography or fractional crystallisation. The enantiomers may be isolated by separation of racemate for example by fractional crystallisation, resolution or HPLC. The diastereomers may be isolated by separation of 20 isomer mixtures for instance by fractional crystallisation, HPLC or flash chromatography. Alternatively the stereoisomers may be made by chiral synthesis from chiral starting materials under conditions, which will not cause racemisation or epimerisation, or by derivatisation, with a chiral reagent. All stereoisomers are included within the scope of the invention.

25 The following definitions shall apply throughout the specification and the appended claims.

30 Unless otherwise stated or indicated, the term "alkyl" denotes either a straight, branched or cyclic alkyl group. Examples of said alkyl include methyl, ethyl, n-propyl, isopropyl,

cyclopropyl, n-butyl, iso-butyl, sec-butyl and t-butyl. Preferred alkyl groups are methyl, ethyl, propyl, isopropyl and tertiary butyl.

Unless otherwise stated or indicated, the term "alkoxy" denotes a group O-alkyl, wherein  
5 alkyl is as defined above.

Unless otherwise stated or indicated, the term "halo" shall mean fluorine, chlorine, bromine or iodine.

10 Specific compounds of the invention include one or more of the following:

2-(3-chlorophenoxy)-*N*-[1-[(1-phenyl-1*H*-pyrrol-3-yl)methyl]piperidin-4-yl]acetamide

2-(3-chlorophenoxy)-*N*-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl)methyl}piperidin-4-yl]acetamide

2-(3-chlorophenoxy)-*N*-(1-{[1-(4-methoxyphenyl)-1*H*-pyrrol-3-yl)methyl}piperidin-4-yl)acetamide  
15

2-(3-chlorophenoxy)-*N*-(1-{[1-(2-chlorophenyl)-1*H*-pyrrol-3-yl)methyl}piperidin-4-yl)acetamide

2-(3-chlorophenoxy)-*N*-[1-({1-[5-(trifluoromethyl)pyridin-2-yl]-1*H*-pyrrol-3-yl)methyl}piperidin-4-yl]acetamide

20 2-(3-chlorophenoxy)-*N*-(1-{[1-(3-chlorophenyl)-1*H*-pyrrol-3-yl)methyl}piperidin-4-yl)acetamide

2-(3-chlorophenoxy)-*N*-[1-(4-pyridin-2-ylbenzyl)piperidin-4-yl]acetamide

2-(3-chlorophenoxy)-*N*-(1-{[5-(4-chlorophenyl)-2-furyl)methyl}piperidin-4-yl)acetamide

2-(3-chlorophenoxy)-*N*-[1-({1-[4-(trifluoromethoxy)phenyl]-1*H*-pyrrol-3-yl)methyl}piperidin-4-yl]acetamide  
25

2-(3-chlorophenoxy)-*N*-(1-[3-(1*H*-pyrrol-1-yl)benzyl]piperidin-4-yl)acetamide

2-(3-chlorophenoxy)-*N*-[1-(3-pyridin-2-ylbenzyl)piperidin-4-yl]acetamide

2-(3-chlorophenoxy)-*N*-(1-{[5-(2,4-dichlorophenyl)-2-furyl)methyl}piperidin-4-yl)acetamide

2-(3-chlorophenoxy)-N-[1-({5-[1-methyl-5-(trifluoromethyl)-1*H*-pyrazol-3-yl]-2-thienyl}methyl)piperidin-4-yl]acetamide

*N*-(1-{[1-(4-bromophenyl)-1*H*-pyrrol-3-yl]methyl}piperidin-4-yl)-2-(3-chlorophenoxy)acetamide

5 2-(3-chlorophenoxy)-*N*-methyl-*N*-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide

2-[(3-chlorophenyl)thio]-*N*-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide

10 2-(pyridin-3-yloxy)-*N*-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide

2-[3-(trifluoromethoxy)phenoxy]-*N*-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide

2-[3-(trifluoromethoxy)phenoxy]-*N*-[1-({1-[5-(trifluoromethyl)pyridin-2-yl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide

15 2-(3-cyanophenoxy)-*N*-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide

2-(3-fluorophenoxy)-*N*-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide

20 2-(3-cyanophenoxy)-*N*-[1-({5-[1-methyl-5-(trifluoromethyl)-1*H*-pyrazol-3-yl]-2-thienyl}methyl)piperidin-4-yl]acetamide

2-(2-chlorophenoxy)-*N*-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide

2-(3-chlorophenoxy)-*N*-[1-({5-[4-(trifluoromethoxy)phenyl]-2-furyl}methyl)piperidin-4-yl]acetamide

25 2-(3-chlorophenoxy)-*N*-(1-{[1-(4-cyanophenyl)-1*H*-pyrrol-3-yl]methyl}piperidin-4-yl)acetamide

2-(3-cyanophenoxy)-*N*-(1-{[5-(2,4-dichlorophenyl)-2-furyl]methyl}piperidin-4-yl)acetamide

2-(3-cyanophenoxy)-N-[1-({1-[4-(trifluoromethoxy)phenyl]-1*H*-pyrrol-3-yl)methyl}piperidin-4-yl]acetamide

2-(3-chlorophenoxy)-N-(1-({1-[5-chloropyrimidin-2-yl]-1*H*-pyrrol-3-yl)methyl}piperidin-4-yl)acetamide

5 3-(3-chlorophenyl)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl)methyl}piperidin-4-yl]propanamide

(2*E*)-3-(3-chlorophenyl)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl)methyl}piperidin-4-yl]acrylamide

10 2-(3,5-difluorophenoxy)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl)methyl}piperidin-4-yl]acetamide

2-(2,6-diisopropylphenoxy)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl)methyl}piperidin-4-yl]acetamide

2-(3-isopropylphenoxy)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl)methyl}piperidin-4-yl]acetamide

15 2-(2-cyanophenoxy)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl)methyl}piperidin-4-yl]acetamide

2-(isoquinolin-5-yloxy)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl)methyl}piperidin-4-yl]acetamide

and pharmaceutically acceptable salts thereof.


20

#### Methods of preparation

25 The compounds of the invention may be prepared as outlined below according to any of the following methods. However, the invention is not limited to these methods, the compounds may also be prepared as described for structurally related compounds in the prior art.


Compounds of formula I may be prepared by reacting a compound of formula II





II

in which X, Y and R<sup>1</sup> are as previously defined,  
with a compound of formula III




III

in which Z and W are as previously defined.


- 10 For example, a compound of formula II and a compound of formula III may be reacted together at a temperature in the range of 0°C to 150°C, preferably in the range of 20°C to 80°C in the presence of a solvent, for example methanol, DCM, CHCl<sub>3</sub>, THF or dioxane, in the presence of a reducing agent, for example sodium cyanoborohydride (optionally polymer supported) or sodium triacetoxyborohydride (optionally polymer supported).
- 15 Optionally, a catalytic amount of an acid, e.g. acetic acid, may be added to the reaction mixture.

Alternatively, compounds of formula I may be prepared by reacting a compound of formula IV,



IV


in which R<sup>1</sup>, Z and W are as previously defined and where L is a leaving group such as halo or methanesulfonyloxy, with a compound of formula V




in which X is as previously defined and in which Q represents a hydroxy or a mercapto group.

For example, a compound of formula IV and a compound of formula V may be reacted together at a temperature in the range of 0°C to 150°C, preferably in the range of 20°C to 80°C in the presence of a solvent, for example acetone, 2-butanone, dioxane, THF, DCM or 1,2-dichloroethane in the presence of a suitable inorganic or organic base, e.g. KOtBu, Cs<sub>2</sub>CO<sub>3</sub>, K<sub>2</sub>CO<sub>3</sub> or NaH, optionally in the presence of a catalytic amount of KI or NaI.

Alternatively, compounds of formula I may be prepared by reacting a compound of formula VI,



in which R<sup>1</sup>, Z and W are as previously defined with a compound of formula VII




in which X and Y are as previously defined and in which S is a hydroxy group or a chlorine atom.

For example, a compound of formula VI and a compound of formula VII, in which S is a hydroxy group, may be reacted together at a temperature in the range of 0°C to 150°C,

preferably in the range of 20°C to 80°C in the presence of a solvent, for example THF, DCM, DCM/water (i.e. a two phase system) or DMF, optionally in the presence of a suitable inorganic or organic base, e.g. DIPEA or TEA, and a standard amide coupling reagent, e.g. HATU, TBTU, EDC, or DCC, the latter two of which may optionally be polymer supported.

Alternatively, compounds of formula I may be obtained by reaction of compounds of formula VII, in which S is chlorine, with compounds of formula VI in an inert solvent, e.g. THF, dioxane, DCM,  $\text{CHCl}_3$  or 1,2-dichloroethane in the presence of a suitable inorganic or organic base, e.g. DIPEA, TEA,  $\text{K}_2\text{CO}_3$  or  $\text{NaHCO}_3$ .


Compounds of formula II may be prepared by reacting a compound of formula VIII



VIII

in which  $\text{R}^1$  are as previously defined, with a compound of formula VII e.g. by using one of the methods hereinbefore described for the reaction of compounds of formulae VI and VII.

Compounds of formula III, in which Z is a pyrrolyl ring, may be prepared by reaction of a compound of formula IX with a compound of formula X in which W is as previously defined.





IX



X

For example, a compound of formula IX and a compound of formula X may be reacted together at a temperature in the range of 20°C to 90°C in acetic acid.



Alternatively, compounds of formula III may be prepared by reaction of a compound of formula XI, in which Z is as previously defined and in which T is bromine or iodine with a compound of formula XII in which W is as previously defined.



10

For example, a compound of formula XI and a compound of formula XII may be reacted together under palladium catalysis using a method described e.g. in Feuerstein, M et al., *Tetrahedr. Lett.* 42 (33), 5659, 2001.


Alternatively, using similar synthetic methodology, compounds of formula III may be prepared by reaction of a compound of formula XIII, in which Z is as previously defined with a compound of formula XIV in which W and T are as previously defined



20

Compounds of formula IV may be prepared by reacting a compound of formula VI with a compound of formula XV, wherein L and S are as previously described, e.g. by using one of the methods hereinbefore described for the reaction of compounds of formulae VI and VII.

25



## XV

Compounds of formula V, VII, VIII and IX-XV are either commercially available or can be prepared by methods well known to those skilled in the art.

5

Optionally, the piperidine ring nitrogen in formulae IV, VI and VIII may be protected prior to reaction with a compound of formula V or VII. Amine protecting groups are known to those skilled in the art, for example the benzyl, t-Boc, or Cbz groups.

10 The compounds of the invention may be isolated from their reaction mixtures using conventional techniques.

Persons skilled in the art will appreciate that, in order to obtain compounds of the invention in an alternative and in some occasions, more convenient manner, the individual process  
15 steps mentioned hereinbefore may be performed in a different order, and/or the individual reactions may be performed at a different stage in the overall route (*i.e.* chemical transformations may be performed upon different intermediates to those associated hereinbefore with a particular reaction).

20 Certain compounds of formulae II, III, IV and VI are novel and are claimed as a further aspect of the present invention as useful intermediates:

2-(3-chlorophenoxy)-*N*-piperidin-4-ylacetamide

2-(3-cyanophenoxy)-*N*-piperidin-4-ylacetamide

25 2-(3-fluorophenoxy)-*N*-piperidin-4-ylacetamide

2-(2-chlorophenoxy)-*N*-piperidin-4-ylacetamide

*N*-piperidin-4-yl-2-(pyridin-3-yloxy)acetamide

*N*-piperidin-4-yl-2-[3-(trifluoromethoxy)phenoxy]acetamide

2-phenoxy-*N*-piperidin-4-ylacetamide

30 2-(3-chlorophenoxy)-*N*-methyl-*N*-piperidin-4-ylacetamide

2-[(3-chlorophenyl)thio]-*N*-piperidin-4-ylacetamide

1-[5-(trifluoromethyl)pyridin-2-yl]-1*H*-pyrrole-3-carbaldehyde

1-(5-chloropyrimidin-2-yl)-1*H*-pyrrole-3-carbaldehyde

4-(3-formyl-1*H*-pyrrol-1-yl)benzonitrile

2-chloro-*N*-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide

5 1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-amine dihydrochloride

*tert*-butyl[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]carbamate

10 The compounds of the invention may be isolated from their reaction mixtures using conventional techniques. Persons skilled in the art will appreciate that, in order to obtain compounds of the invention in an alternative and in some occasions, more convenient manner, the individual process steps mentioned hereinbefore may be performed in a different order, and/or the individual reactions may be performed at a different stage in the overall route (i.e. chemical transformations may be performed upon different intermediates to those associated hereinbefore with a particular reaction). The expression "inert solvent" refers to a solvent, which does not react with the starting materials, reagents, intermediates or products in a manner, which adversely affects the yield of the desired product.

20 Pharmaceutical preparations

The compounds of the invention will normally be administered via the oral, parenteral, intravenous, intramuscular, subcutaneous or in other injectable ways, buccal, rectal, vaginal, transdermal and/or nasal route and/or via inhalation, in the form of pharmaceutical preparations comprising the active ingredient either as a free base, or a pharmaceutically acceptable inorganic or organic addition salt, in a pharmaceutically acceptable dosage form. Depending upon the disorder and patient to be treated and the route of administration, the compositions may be administered at varying doses.

30 Suitable daily doses of the compounds of the invention in the therapeutic treatment of humans are about 0.001-10 mg/kg body weight, preferably 0.01-3 mg/kg body weight.

Oral formulations are preferred particularly tablets or capsules which may be formulated by methods known to those skilled in the art to provide doses of the active compound in the range of 0.5 mg to 500mg for example 1 mg, 3 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg and 250 mg.

According to a further aspect of the invention there is also provided a pharmaceutical formulation including any of the compounds of the invention, or pharmaceutically acceptable derivatives thereof, in admixture with pharmaceutically acceptable adjuvants, diluents and/or carriers.

The compounds of the invention may also be combined with other therapeutic agents, which are useful in the treatment of disorders associated with obesity, psychiatric disorders, neurological disorders and pain.

#### Pharmacological properties

The compounds of formula (I) are useful for the treatment of obesity, psychiatric disorders such as psychotic disorders, anxiety, anxio-depressive disorders, depression, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Raynaud's syndrome, Parkinson's disease, Huntington's chorea and Alzheimer's disease. The compounds are also potentially useful for the treatment of immune, cardiovascular, reproductive and endocrine disorders, and diseases related to the respiratory and gastrointestinal systems. The compounds are also potentially useful as agents for ceasing consumption of tobacco, treating nicotine dependence and/or treating nicotine withdrawal symptoms, reducing the craving for nicotine and as anti-smoking agents. The compounds may also eliminate the increase in weight that normally accompanies the cessation of smoking. The compounds are also potentially useful as agents for treating or preventing diarrhea.

The compounds are also potentially useful as agents for reducing the craving/relapse for addictive substances that include, but are not limited to psychomotor-active agents such as nicotine, alcohol, cocaine, amphetamines, opiates, benzodiazepines and barbiturates. The

compounds are also potentially useful as agents for treating drug addiction and/or drug abuse.

Accordingly, it is desirable to provide a compound and method of treatment which will be  
5 active in reducing craving for the abused substance, and which does not exacerbate the sympathetic response rate caused by the abused substance and which has favourable pharmacodynamic effects.

The compounds are also potentially useful as agents for treating pain disorders, including  
10 but not limited to acute and chronic nociceptive, inflammatory and neuropathic pain and migraine.

In another aspect the present invention provides a compound of formula I as claimed in any previous claim for use as a medicament.

15

In a further aspect the present invention provides the use of a compound of formula I in the preparation of a medicament for the treatment or prophylaxis of obesity, psychiatric disorders such as psychotic disorders, anxiety, anxio-depressive disorders, depression, bipolar disorder, ADHD, cognitive disorders, memory disorders, schizophrenia, epilepsy,  
20 and related conditions, neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders, including but not limited to acute and chronic nociceptive, inflammatory and neuropathic pain and migraine, comprising administering a pharmacologically effective amount of a compound of formula I to a patient in need thereof.

25

In a still further aspect the present invention provides a method of treating obesity, psychiatric disorders such as psychotic disorders, anxiety, anxio-depressive disorders, depression, bipolar disorder, ADHD, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as  
30 dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders, including but not limited to acute and chronic nociceptive, inflammatory and neuropathic pain and migraine, comprising administering a



pharmacologically effective amount of a compound of formula I to a patient in need thereof.

The compounds of the present invention are particularly suitable for the treatment of obesity.

In another aspect the present invention provides a method of treating obesity, type II diabetes, Metabolic syndrome and a method of preventing type II diabetes comprising administering a pharmacologically effective amount of a compound of formula I to a patient in need thereof.

#### Combination Therapy

The compounds of the invention may be combined with another therapeutic agent that is useful in the treatment of disorders associated with the development and progress of atherosclerosis such as hypertension, hyperlipidaemias, dyslipidaemias, diabetes and obesity. For example, a compound of the present invention may be used in combination with a compound that affects thermogenesis, lipolysis, fat absorption, satiety, or gut motility. The compounds of the invention may be combined with another therapeutic agent that decreases the ratio of LDL:HDL or an agent that causes a decrease in circulating levels of LDL-cholesterol. In patients with diabetes mellitus the compounds of the invention may also be combined with therapeutic agents used to treat complications related to micro-angiopathies.

The compounds of the invention may be used alongside other therapies for the treatment of metabolic syndrome or type 2 diabetes and its associated complications; these include biguanide drugs, insulin (synthetic insulin analogues), oral antihyperglycemics (these are divided into prandial glucose regulators and alpha-glucosidase inhibitors) and PPAR modulating agents.

In another aspect of the invention, the compound of formula I, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, may be administered in association with a PPAR modulating agent. PPAR modulating agents include but are not

limited to a PPAR alpha and/or gamma agonist, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof. Suitable PPAR alpha and/or gamma agonists, pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof are well known in the art.

5

In addition the combination of the invention may be used in conjunction with a sulfonylurea. The present invention also includes a compound of the present invention in combination with a cholesterol-lowering agent. The cholesterol-lowering agents referred to in this application include but are not limited to inhibitors of HMG-CoA reductase (3-  
10 hydroxy-3-methylglutaryl coenzyme A reductase). Suitably the HMG-CoA reductase inhibitor is a statin.

In the present application, the term "cholesterol-lowering agent" also includes chemical modifications of the HMG-CoA reductase inhibitors, such as esters, prodrugs and  
15 metabolites, whether active or inactive.

The present invention also includes a compound of the present invention in combination with an inhibitor of the ileal bile acid transport system (IBAT inhibitor). The present invention also includes a compound of the present invention in combination with a bile  
20 acid binding resin.

According to an additional further aspect of the present invention there is provided a combination treatment comprising the administration of an effective amount of a compound of the formula I, or a pharmaceutically acceptable salt, solvate, solvate of such a  
25 salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier, with the simultaneous, sequential or separate administration one or more of the following agents selected from:

- a CETP (cholesteryl ester transfer protein) inhibitor;
- a cholesterol absorption antagonist;
- 30 a MTP (microsomal transfer protein) inhibitor ;
- a nicotinic acid derivative, including slow release and combination products;
- a phytosterol compound ;

probucol;

an anti-obesity compound, for example orlistat (EP 129,748) and sibutramine (GB 2,184,122 and US 4,929,629);

an antihypertensive compound, for example an angiotensin converting enzyme (ACE) inhibitor, an angiotensin II receptor antagonist, an adrenergic blocker, an alpha adrenergic blocker, a beta adrenergic blocker, a mixed alpha/beta adrenergic blocker, an adrenergic stimulant, calcium channel blocker, an AT-1 receptor blocker, a saluretic, a diuretic or a vasodilator;

a CB1 antagonist or inverse agonist, for example rimonabant;

another melanin concentrating hormone (MCH) antagonist;

a PDK inhibitor; or

modulators of nuclear receptors for example LXR, FXR, RXR, and RORalpha;

an SSRI;

a serotonin antagonist;

or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier to a warm-blooded animal, such as man in need of such therapeutic treatment.

Therefore in an additional feature of the invention, there is provided a method for the treatment of type 2 diabetes and its associated complications in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof in simultaneous, sequential or separate administration with an effective amount of a compound from one of the other classes of compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

Therefore in an additional feature of the invention, there is provided a method of treating hyperlipidemic conditions in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof in simultaneous, sequential or separate administration with an

effective amount of a compound from one of the other classes of compounds described in this combination section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

- 5 According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula I, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and a compound from one of the other classes of compounds described in this combination section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in association with a  
10 pharmaceutically acceptable diluent or carrier.

According to a further aspect of the present invention there is provided a kit comprising a compound of formula I, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and a compound from one of the other classes of compounds  
15 described in this combination section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

According to a further aspect of the present invention there is provided a kit comprising:

- a) a compound of formula I, or a pharmaceutically acceptable salt, solvate, solvate of such  
20 a salt or a prodrug thereof, in a first unit dosage form;  
b) a compound from one of the other classes of compounds described in this combination section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof; in a second unit dosage form; and  
c) container means for containing said first and second dosage forms.

25 According to a further aspect of the present invention there is provided a kit comprising:

- a) a compound of formula I, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, together with a pharmaceutically acceptable diluent or carrier, in a first unit dosage form;  
30 b) a compound from one of the other classes of compounds described in this combination section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in a second unit dosage form; and

c) container means for containing said first and second dosage forms.

According to another feature of the invention there is provided the use of a compound of the formula I, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment of metabolic syndrome or type 2 diabetes and its associated complications in a warm-blooded animal, such as man.

According to another feature of the invention there is provided the use of a compound of the formula I, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment of hyperlipidaemic conditions in a warm-blooded animal, such as man.

According to a further aspect of the present invention there is provided a combination treatment comprising the administration of an effective amount of a compound of the formula I, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier, with the simultaneous, sequential or separate administration of an effective amount of one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier to a warm-blooded animal, such as man in need of such therapeutic treatment.

#### Experimental section

The invention will now be described in more detail with the following examples that are not to be construed as limiting the invention.

#### Abbreviations

aq.                      aqueous

	Ac	acetyl
	Bu	butyl
	tBoc	<i>tert</i> -butyloxycarbonyl
	Cbz	benzyloxycarbonyl
5	CHO	Chinese hamster ovary (cells)
	DCM	dichloromethane
	DIPEA	di-isopropyl ethyl amine
	DMA	dimethyl acetamide
	DMF	<i>N,N</i> -dimethylformamide
10	DTT	dithiothreitol
	EDC	1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
	EDTA	ethylenediamine tetraacetic acid
	ELS	evaporative light scattering
	ESI	electrospray ionization
15	Et	ethyl
	GDP	guanosine 5'-diphosphate
	HATU	O-(azabenzotriazol-1-yl)-N, N, N', N'-tetramethyluronium hexafluoro-phosphate
	HEK	human embryonic kidney (cells)
20	HEPES	N-2-hydroxyethyl piperazine-N'-2-ethanesulfonic acid
	HPLC	high performance liquid chromatography
	LC	liquid chromatography
	MP-BH(OAc) <sub>3</sub> :	macroporous polymer bound triacetoxymethylborohydride (available from Argonaut)
25	MS	mass spectroscopy
	Pol-BH <sub>3</sub> CN	(polystyrylmethyl)trimethylammonium cyanoborohydride (loading 4.1-4.3 mmol BH <sub>3</sub> CN/g)
	Pol-CHO	4-benzyloxybenzaldehyde polystyrene (loading ~2.66 mmol CHO/g)
30	TBTU	N, N, N', N'-tetramethyl-O-(benzotriazol-1-yl)uronium tetrafluoroborate
	TEA	triethylamine
	TFA	trifluoroacetic acid

	THF	tetrahydrofuran
	TLC	thin layer chromatography
	Tris	trishydroxymethylaminomethane
	Tween	polyoxyethylene sorbitan monolaurate
5	<i>t</i>	tert
	rt.	room temperature
	sat.	saturated
	br	broad
	bs	broad singlet
10	d	doublet
	dd	doublet of doublets
	m	multiplet
	q	quartet
	s	singlet
15	t	triplet

### General Experimental Procedures

Flash column chromatography employed MERCK normal phase silica gel 60 Å (40-63 µm) or a Biotage Horizon Pioneer® HPFC system equipped with FLASH 12+M or  
20 FLASH 25+M or 40+M silica cartridges. Mass spectra were recorded on a Waters Micromass ZQ single quadrupole equipped with a pneumatically assisted electrospray interface (LC-MS).

HPLC analyses were performed on a Gynkotek P580 HPG, gradient pump with a  
25 Gynkotek UVD 170S UV-Vis detector. Column: Chromolith Performance RP-18e, 4.6 x 100 mm, Mobile phase A: Acetonitrile, Mobile phase B: 0.1% TFA (aq), Flow: 3 ml/min, Injection volume: 20 µl, Detection: 254 and 275 nm.

Purifications were performed on a semi preparative HPLC, Shimadzu LC-8A, Shimadzu  
30 SPD-10A UV-vis. detector equipped with a Waters X-terra® Prep MS C<sub>18</sub> Column, 250 mm x 50 mm (10 µm) or on a Waters Prep LC 2000 with UV-detection, equipped with a Kromasil 10 µm C8 250 mm x 20 mm column, or on a semi preparative HPLC, Shimadzu

LC-8A, Shimadzu SPD-10A UV-vis.-detector equipped with a Waters Symmetry® 100 mm x 19 mm C18 5 µm column.

Automated HPLC purification was done using a Waters Fraction Lynx system equipped with UV, ELS and MS detection and an Ace C8 5µ 10 cm x 21,2 id column. The mobile phase was A: 95% CH<sub>3</sub>CN and B: 5% CH<sub>3</sub>CN + 95% 0,1 M NH<sub>4</sub>OAc with a gradient from 100% B to 100% A in 10 minutes at 25 mL/min flow rate.

<sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were obtained at 298 K on a Varian Unity Plus 400 MHz, or a Varian Inova 500 MHz or a Varian Unity Plus 600 MHz or a Bruker Avance 300 MHz or Varian Gemini 2000 300 MHz. Chemical shifts are given in ppm with the solvent residual peak as internal standard: CDCl<sub>3</sub> δ<sub>H</sub> 7.26, δ<sub>C</sub> 77.2; MeOH-*d*<sub>4</sub> δ<sub>H</sub> 3.31, δ<sub>C</sub> 49.0; DMSO-*d*<sub>6</sub> δ<sub>H</sub> 2.50; δ<sub>C</sub> 39.5 ppm.

Microwave heating was performed using single node heating in a Smith Creator from Personal Chemistry, Uppsala, Sweden.

Chemical names (IUPAC) were generated using the software ACD/ Name version 6.00.

Names/reference numbers of starting materials (CAS no), either commercially available or prepared according to literature procedures.

5-[4-(trifluoromethoxy)phenyl]-2-furaldehyde, 306935-95-5; 5-(2,4-dichlorophenyl)-2-furaldehyde, 56300-69-7; *tert*-butyl piperidin-4-ylcarbamate, 73874-95-0; 3-(3-chlorophenyl) propanoic acid, 21640-48-2; (*E*)-3-(3-chlorophenyl) acrylic acid, 14473-90-6; chloroacetic acid, 79-11-8; 3,5-difluorophenol, 2713-34-0; 2-hydroxybenzonitrile, 611-20-1; isoquinolin-5-ol, 2439-04-5; 2,6-di-isopropylphenol, 2078-54-8; 3-isopropylphenol, 618-45-1; 4-aminobenzotrifluoride, 455-14-1; 4-amino-benzonitrile, 873-74-5; 5-formyl-2-furylboronic acid, 27329-70-0; 2-amino-5-chloropyrimidine, 5428-89-7; 4-pyridin-2-ylbenzaldehyde, 127406-56-8; 5-(4-chlorophenyl)-2-furaldehyde, 34035-03-5; 1-[4-(trifluoromethoxy)phenyl]-1*H*-pyrrole-3-carbaldehyde, 439094-17-4; 3-(1*H*-pyrrol-1-yl)benzaldehyde, 129747-77-9; 3-pyridin-2-ylbenzaldehyde, 85553-53-3; 5-(2,4-



dichlorophenyl)-2-furaldehyde, 56300-69-7; 1-(4-bromophenyl)-1*H*-pyrrole-3-carbaldehyde, 477850-19-4; 5-[1-methyl-5-(trifluoromethyl)-1*H*-pyrazol-3-yl]thiophene-2-carbaldehyde, 175202-93-4; aniline, 62-53-3; 1-benzylpiperidin-4-amine, 50541-93-0; chloroacetyl chloride, 74-04-9; 2-chloroaniline, 95-51-2; 3-chloroaniline, 108-42-9; 1-chloroethyl chloroformate, 50893-53-3; 2-chlorophenol, 95-57-8; 3-chlorophenol, 108-43-0; 2,5-dimethoxy-3-tetrahydrofuran-2-carboxaldehyde, 50634-05-4; 3-fluorophenol, 372-20-3; 108-43-0; 3-hydroxy-benzonitrile, 873-62-1; 5-trifluoromethyl-pyridine-2-ylamine, 74784-70-6; 3-hydroxypyridine, 109-00-2; 3-chlorothiophenol, 2037-31-2; phenol, 108-95-2; *tert*-butyl 4-aminopiperidine-1-carboxylate, 87120-72-7; 3-(trifluoromethoxy)phenol, 827-99-6; 4-methoxyaniline, 104-94-9.

### Preparation of Intermediates

#### Example A

#### 15 2-(3-chlorophenoxy)-*N*-piperidin-4-ylacetamide

##### i) *N*-(1-benzylpiperidin-4-yl)-2-chloroacetamide

Chloroacetyl chloride (1.68 mL, 21.1 mmol) was added dropwise to a stirred solution of 1-benzylpiperidin-4-amine (3.65 g, 19.2 mmol) in DCM (65 mL). The mixture was stirred  
20 for 2 h at rt. whereafter additional DCM (100 mL) was added. The organic phase was washed with NaHCO<sub>3</sub> (3 x 100 mL, aq., sat.), dried over MgSO<sub>4</sub> and concentrated to give 4.43 g (86%) of the title compound as an off-white solid. This material was used in the next step without further purification.

<sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 8.11 (br d, 1 H), 7.20-7.35 (m, 5H), 4.00 (s, 2H), 3.53 (m, 1H),  
25 3.44 (s, 2H), 2.73 (m, 2H), 2.00 (m, 2H), 1.69 (m, 2H), 1.34-1.48 (m, 2H). MS (ESI) 267 (M + H<sup>+</sup>).

##### ii) *N*-(1-benzylpiperidin-4-yl)-2-(3-chlorophenoxy)acetamide

Potassium *tert*-butoxide (2.24 g, 19.0 mmol) was added portionwise to a solution of 3-chlorophenol (2.33 g, 18.1 mmol) in THF (75 mL) and the mixture was stirred at rt. until a  
30 clear solution was obtained. *N*-(1-benzylpiperidin-4-yl)-2-chloroacetamide (4.39 g, 16.5 mmol) dissolved in THF (50 mL) was added dropwise over 10 minutes and the mixture

was stirred for 4 h after which additional potassium *tert*-butoxide (0.2 g, 1.8 mmol) was added followed by further stirring at rt. for 1 h. Water (50 mL) was added and the mixture was concentrated. The aqueous residue was extracted with EtOAc (3 x 75 mL) and the combined organic phases were washed with 1 M NaOH (75 mL). The organic phase was concentrated and the residue was purified on silica gel eluted with DCM:MeOH (98:2) to give 5.15 g (87%) of the title compound as a off-white solid.

<sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 7.96 (br d, 1H), 7.22-7.35 (m, 6H), 6.99-7.04 (m, 2H), 6.93 (m, 1H), 4.49 (s, 2H), 3.63 (m, 1H), 3.44 (s, 2H), 2.74 (m, 2H), 1.99 (m, 2H), 1.68 (m, 2H), 1.43-1.55 (m, 2H). MS (ESI) 360 (M + H<sup>+</sup>).

### iii) 2-(3-chlorophenoxy)-*N*-piperidin-4-ylacetamide

1-Chloroethyl chloroformate (2.04 g, 14.3 mmol) was added to a solution of *N*-(1-benzylpiperidin-4-yl)-2-(3-chlorophenoxy)acetamide (4.1 g, 11.4 mmol) in dichloroethane (70 mL) and the mixture was heated at reflux for 1 h. The reaction mixture was concentrated and methanol (70 mL) was added and heated to reflux for 17 h (over night). The reaction mixture was concentrated and the residue was dissolved in HCl diluted with water (100 mL) and extracted with Et<sub>2</sub>O (2 x 75 mL). The aqueous phase was made basic with 2M NaOH and extracted with EtOAc (2 x 150 mL). The combined organic phases were concentrated and the residue was purified on silica gel eluted with first DCM:MeOH (9:1) followed by DCM:MeOH (8:2) containing 1% TEA and finally with DCM:MeOH (7:3) containing 1% TEA, to give 2.25 g (73%) of the title compound.

<sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 7.97 (br d, 1H), 7.31 (t, 1H), 7.02-7.05 (m, 2H), 6.92 (dd, 1H), 4.49 (s, 2H), 3.66 (m, 1H), 2.90 (m, 2H), 2.46 (m, 2H), 1.62 (m, 2H), 1.24-1.39 (m, 2H). MS (ESI) 269 (M + H<sup>+</sup>).

Using the method described in Example A, the compounds of Examples B and D were similarly prepared from *N*-(1-benzylpiperidin-4-yl)-2-chloroacetamide and the appropriate phenols:

### Example B

#### 2-(3-cyanophenoxy)-*N*-piperidin-4-ylacetamide

The crude product was purified on silica gel eluted with first DCM:MeOH (9:1) followed by DCM:MeOH (8:2) containing 1% TEA and finally with DCM:MeOH (7:3) containing 1% TEA, to give the title compound in 34% yield (two steps).

<sup>1</sup>H NMR (CDCl<sub>3</sub>, conformer mixture, \* denotes minor conformer peaks) δ 7.43 (t, 1H), 7.33 (br d, 1H), 7.13-7.25 (m, 2H), 6.49 (d br, 1H), 6.34\* (d br, 1H), 4.49 (s, 2H), 4.01 (m, 1H), 3.89\* (m, 1H), 3.12-3.25 (m, 3H), 2.85-2.95\* (m, 2H), 2.70-2.82 (m, 2H), 2.06-2.16\* (m, 2H), 1.88-2.03 (m, 2H), 1.42-1.58 (m, 2H).

<sup>13</sup>C NMR (CDCl<sub>3</sub>, conformer mixture, \* denotes minor conformer peaks) δ 166.4, 157.3, 130.9, 126.1, 119.6, 119.5\*, 118.4, 118.3\*, 113.8, 67.6, 53.5\*, 50.6\*, 46.9\*, 46.4, 45.0, 32.5, 32.2\*.

MS (ESI) 260.2 (M + H<sup>+</sup>).

#### Example C

##### 2-(3-fluorophenoxy)-N-piperidin-4-ylacetamide

The crude product was purified on silica gel eluted with first DCM:MeOH (9:1) followed by DCM:MeOH (9:1) containing 1% NH<sub>3</sub> (aq.) and finally with DCM:MeOH (8:2) containing 1% NH<sub>3</sub> (aq.), to give the title compound in 61% overall yield (two steps).

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.27 (m, 1H), 6.78-6.64 (m, 3H), 6.41 (br d, 1H), 4.45 (s, 2H), 3.97 (m, 1H), 3.07 (m, 2H), 2.71 (m, 2H), 1.95 (m, 2H), 1.76 (m, 4H), 1.44-1.31 (m, 2H).

<sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 166.9, 163.7 (d, J = 247 Hz), 158.4 (d, J = 11 Hz), 130.8 (d, J = 10 Hz), 110.3, 109.2 (d, J = 21 Hz), 102.9 (d, J = 26 Hz), 67.6, 46.7, 45.4, 33.3.

MS (ESI) 253.3 (M + H<sup>+</sup>).

#### Example D

##### 2-(2-chlorophenoxy)-N-piperidin-4-ylacetamide

The crude product was purified on silica gel eluted with first DCM:MeOH (9:1) followed by DCM:MeOH (8:2) containing 1% TEA to give the title compound in 24% overall yield (two steps):

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.37-7.39 (m, 1H), 7.20-7.26 (m, 1H), 6.95-7.00 (m, 2H), 6.87-6.89 (m, 1H), 4.52 (s, 2H), 4.09 (m, 1H), 3.40-3.60 (m, 3H), 3.03 (m, 2H), 2.20 (m, 2H), 1.92-2.0 (m, 2H).

<sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 167.5, 152.8, 130.6, 128.3, 123.3, 123.2, 114.4, 68.3, 44.3, 43.0, 28.6.

MS (ESI) 269.2 ( $M + H^+$ ).

### Example E

#### *N*-piperidin-4-yl-2-(pyridin-3-yloxy)acetamide

##### 5 i) *tert*-Butyl 4-[(chloroacetyl)amino]piperidine-1-carboxylate

A mixture of *tert*-butyl 4-aminopiperidine-1-carboxylate (5.0 g, 25 mmol) and chloroacetyl chloride (3.1 g, 27.5 mmol) in DCM (50 mL) was stirred at rt. under  $N_2$  atmosphere until TLC indicated that starting material was consumed (2.5 h). The mixture was diluted with DCM and washed with sat. aq.  $NaHCO_3$ . The organic layer was separated and the solvent  
10 was removed. The residue was purified on silica gel eluted with DCM:MeOH (9:1) to give 6 g (87%) of the title compound.

$^1H$  NMR ( $CDCl_3$ )  $\delta$  6.47 (br s, 1H), 3.86-4.16 (m, 5H), 2.79-2.96 (m, 2H), 1.82-2.0 (m, 2H), 1.28-1.53 (m, 11H).

MS (ESI) 277 ( $M + H^+$ ).

15

##### ii) *tert*-Butyl 4-[(pyridin-3-yloxy)acetyl]amino]piperidine-1-carboxylate

Potassium *tert*-butoxide (1.14 g, 10.1 mmol) was added to a solution of 3-hydroxypyridine (1.03 g, 10.8 mmol) in THF (50 mL) and the mixture was stirred at rt for 20 minutes. *tert*-Butyl 4-[(chloroacetyl)amino]piperidine-1-carboxylate (2.0 g, 7.2 mmol) in THF (20 mL)  
20 was added dropwise over 5 minutes and the mixture was stirred at rt. until LC-MS indicated that starting material was consumed. The mixture was concentrated and the residue was dissolved in  $H_2O$  (100 mL) and subsequently extracted with EtOAc (3x 70 mL). The combined organic phases were washed with brine (60 mL), dried ( $Na_2SO_4$ ) and concentrated. The residue was purified on silica gel eluted with DCM:MeOH (9:1) to give  
25 1.01 g (42%) of the title compound.

$^1H$  NMR ( $CDCl_3$ )  $\delta$  8.41-8.24 (m, 2H), 7.32-7.18 (m, 2H), 6.43 (br d,  $J = 7.5$  Hz, 1H), 4.52 (s, 2H), 4.18-3.95 (m, 3H), 2.87 (m, 2H), 1.93 (m, 2H), 1.45 (s, 9H), 1.50-1.30 (m, 2H).

MS (ESI) 336 ( $M + H^+$ ).

**iii) *N*-Piperidin-4-yl-2-(pyridin-3-yloxy)acetamide**

To a solution of *tert*-butyl 4-[[pyridin-3-yloxy)acetyl]amino]piperidine-1-carboxylate (1.01 g, 3.0 mmol) in DCM (30 mL) was added TFA (5 mL) and the mixture was stirred at rt. until LC-MS indicated that starting material was consumed. The reaction mixture was concentrated and the residue was dissolved in EtOAc (200 mL) and washed with 1M NaOH (2x 50 mL) and brine (50 mL). After drying (Na<sub>2</sub>SO<sub>4</sub>) the organic phase was evaporated to dryness. The aqueous phase was extracted with DCM (3x 80 mL) and the combined organic phases were washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>) and evaporated. The combined residues were dissolved in DCM, filtered and evaporated. The residue was purified on silica gel eluted with DCM:MeOH:NEt<sub>3</sub> (gradient from 90:10:1 to 60:40:1) to give 0.46 g (65%) of the title compound as a sticky oil. The material was solidified by treatment with DCM/Et<sub>2</sub>O followed by evaporation.

<sup>1</sup>H NMR (MeOD-*d*<sub>4</sub>) δ 8.32 (d, *J* = 2.4 Hz, 1H), 8.18 (m, 1H), 7.50-7.35 (m, 2H), 4.61 (s, 2H), 3.89 (m, 1H), 3.09 (m, 2H), 2.69 (m, 2H), 1.88 (m, 2H), 1.52 (m, 2H).

<sup>13</sup>C NMR (MeOD-*d*<sub>4</sub>) δ 169.4, 156.1, 143.2, 138.9, 125.8, 123.5, 68.3, 47.9, 45.7, 32.7.

MS (ESI) 236 (M + H<sup>+</sup>).

Using the method described in Example E, the compounds of Examples F and G were similarly prepared from *tert*-butyl 4-[(chloroacetyl)amino]piperidine-1-carboxylate and the appropriate phenols:

**Example F*****N*-piperidin-4-yl-2-[3-(trifluoromethoxy)phenoxy]acetamide**

Overall yield (two steps) 56%.

<sup>1</sup>H NMR (MeOD-*d*<sub>4</sub>) δ 7.33-7.44 (m, 1H), 6.86-7.03 (m, 3H), 4.54 (s, 2H), 3.81-3.95 (m, 1H), 3.01-3.13 (m, 2H), 2.60-2.73 (m, 2H), 1.78-1.92 (m, 2H), 1.40-1.57 (m, 2H).

<sup>13</sup>C NMR (MeOD-*d*<sub>4</sub>) δ 169.7, 160.4, 151.4, 131.8, 121.9 (q, *J* = 255 Hz), 114.9, 114.4, 109.4, 68.4, 48.0, 45.8, 32.9. MS (ESI) 319.2 (M + H<sup>+</sup>).

**Example G****2-phenoxy-*N*-piperidin-4-ylacetamide**

Overall yield (two steps) 45%

$^1\text{H}$  NMR (MeOD- $d_4$ )  $\delta$  6.91-7.03 (m, 3H), 7.23-7.34 (m, 2H), 4.48 (s, 2H), 3.81-3.96 (m, 1H), 3.01-3.06 (m, 2H), 2.60-2.69 (m, 2H), 1.82-1.86 (m, 2H), 1.41-1.55 (m, 2H).

$^{13}\text{C}$  NMR (MeOD- $d_4$ )  $\delta$  170.2, 159.2, 130.6, 122.8, 115.8, 68.2, 47.9, 45.8, 32.9.

5 MS (ESI) 235.3 ( $\text{M} + \text{H}^+$ ).

### Example H

#### 1-[4-(trifluoromethyl)phenyl]-1H-pyrrole-3-carbaldehyde

To a solution of 2,5-dimethoxy-3-tetrahydrofurancarboxaldehyde (8.0 g, 49.9 mmol) in acetic acid (120 mL) was added 4-aminobenzotrifluoride (8.05 g, 49.9 mmol) and the mixture was heated at reflux under an atmosphere of nitrogen until HPLC indicated that starting material was consumed. The reaction mixture was concentrated and the residue was dissolved in EtOAc (500mL) and washed with 2M NaOH (aq) (100 mL) and brine. The organic phase was dried ( $\text{Na}_2\text{SO}_4$ ) and then evaporated to dryness. The residue was purified on  $\text{SiO}_2$  eluted with DCM and finally DCM:MeOH (98:2) to give 8.56 g (72%) of the title compound (94% pure, HPLC purity).

$^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  9.87 (s, 1H), 7.76 (m, 2H), 7.72 (m, 1H), 7.55 (m, 2H), 7.14 (m, 1H), 6.84 (m, 1H).

$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  185.5, 142.2, 129.4 (q,  $J = 33$  Hz), 129.0, 127.4 (q,  $J = 4$  Hz), 126.8, 123.8 (q,  $J = 272$  Hz), 122.1, 121.1, 110.5.

20 MS (ESI) 240 ( $\text{M} + \text{H}^+$ ).

Using the method described in Example H, the compounds of Examples I, J K, L, M, N and O were similarly prepared from 2,5-dimethoxy-3-tetrahydrofurancarboxaldehyde and the appropriate aromatic amine:

### Example I

#### 1-phenyl-1H-pyrrole-3-carbaldehyde

MS (ESI) 272 ( $\text{M} + \text{H}^+$ ).

### Example J

#### 1-(2-chlorophenyl)-1H-pyrrole-3-carbaldehyde

<sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 9.78 (s, 1H), 7.93 (m, 1H), 7.68-7.74 (m, 1H), 7.50-7.60 (m, 3H), 7.17 (m, 1H), 6.66 (m, 1H).  
MS (ESI) 206.2 (M + H<sup>+</sup>).

5 **Example K**

**1-(3-chlorophenyl)-1*H*-pyrrole-3-carbaldehyde**

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 9.85 (s, 1H), 7.65 (m, 1H), 7.45-7.36 (m, 2H), 7.35-7.28 (m, 2H), 7.07 (m, 1H), 6.80 (m, 1H).

<sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 185.5, 140.6, 135.7, 131.1, 128.6, 127.5, 127.0, 122.3, 121.5, 119.3,  
10 110.1.

MS (ESI) 206 (M + H<sup>+</sup>).

**Example L**

**1-[5-(trifluoromethyl)pyridin-2-yl]-1*H*-pyrrole-3-carbaldehyde**

15 MS (ESI) 241 (M + H<sup>+</sup>).

**Example M**

**1-(4-methoxyphenyl)-1*H*-pyrrole-3-carbaldehyde**

MS (ESI) 202 (M + H<sup>+</sup>).

20

**Example N**

**1-(5-chloropyrimidin-2-yl)-1*H*-pyrrole-3-carbaldehyde**

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 9.90 (s, 1H), 8.63 (s, 2H), 8.36 (m, 1H), 7.76 (m, 1H), 6.78 (m, 1H).

<sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 185.8, 157.2, 153.6, 129.5, 128.2, 127.6, 121.6, 110.2.

25

**Example O**


**4-(3-formyl-1*H*-pyrrol-1-yl)benzonitrile**

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 9.88 (s, 1H), 7.80 (d, 2H), 7.73 (m, 1H), 7.55 (d, 2H), 7.15 (m, 1H), 6.86 (m, 1H).

<sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 185.4, 134.1, 129.2, 126.6, 124.6, 121.8, 121.1, 118.0, 110.8.

30

MS (ESI, direct inlet) 197.2 (M + H<sup>+</sup>).



### Working Examples

#### **Example 1**

5 **2-(3-chlorophenoxy)-N-[1-[(1-phenyl-1H-pyrrol-3-yl)methyl]piperidin-4-yl]acetamide**  
2-(3-chlorophenoxy)-N-piperidin-4-ylacetamide (0.3 g, 1.1 mmol) and 1-phenyl-1H-pyrrole-3-carbaldehyde (0.2 g, 1.2 mmol) was dissolved in dichloroethane (7 mL). Sodiumtriacetoxyborohydride (0.37 g, 1.75 mmol) was then added and the mixture was stirred at rt. until LC-MS indicated that starting material was consumed. NaHCO<sub>3</sub> (10 mL,  
10 aq., sat.) was added, the aqueous phase was extracted with DCM (2 x 10 mL) and concentrated. The residue was purified on silica gel eluting with DCM:MeOH (95:5) to give 0.1 g (21%) of the title compound.

<sup>1</sup>H NMR (MeOD-d<sub>4</sub>) δ 7.37-7.50 (m, 4H), 7.18-7.30 (m, 2H), 7.12-15 (m, 2H), 6.97-7.04 (m, 2H), 6.89 (dd, 1H), 6.28 (m, 1H), 4.48 (s, 2H), 3.77 (m, 1H), 3.47 (s, 2H), 2.96 (m,  
15 2H), 2.15 (m, 2H), 1.84 (m, 2H), 1.53-1.68 (m, 2H).

<sup>13</sup>C NMR (MeOD-d<sub>4</sub>) δ 169.8, 160.0, 141.8, 136.0, 131.7, 130.7, 126.5, 122.8, 121.8, 120.8, 120.3, 120.2, 116.5, 114.5, 114.3, 113.1, 68.3, 55.9, 52.9, 47.8, 31.9.

MS (ESI) 424 (M + H<sup>+</sup>).

20 Using the synthetic method described in Example 1, the compounds of Examples 2-6 were similarly prepared from 2-(3-chlorophenoxy)-N-piperidin-4-ylacetamide and the appropriate aldehyde:

#### **Example 2**

25 **2-(3-chlorophenoxy)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl)methyl}piperidin-4-yl]acetamide**

The residue after workup was purified on silica gel eluted with DCM:MeOH (95:5) to give 0.7 g (83%) of the title compound as a sticky oil. The material was triturated with a mixture of heptane/EtOAc, followed by treatment with Et<sub>2</sub>O. Filtration of the solid  
30 material afforded 0.160 g of the title compound as a white solid.



<sup>1</sup>H NMR (MeOD-d<sub>4</sub>) δ 7.81-7.71 (m, 4H), 7.57 (m, 1H), 7.43 (m, 1H), 7.28 (t, 1H), 7.05-6.91 (m, 3H), 6.51 (m, 1H), 4.54 (s, 2H), 4.23 (s, 2H), 4.05 (m, 1H), 3.54 (m, 2H), 3.12 (m, 2H), 2.13 (m, 2H), 1.93 (m, 2H).

<sup>13</sup>C NMR (MeOD-d<sub>4</sub>) δ 170.2, 160.0, 143.9, 135.9, 131.7, 128.9 (q, *J* = 33 Hz), 128.1 (q, *J* = 4 Hz), 125.4 (q, *J* = 271 Hz), 123.1, 122.8, 121.7, 121.1, 116.4, 115.4, 114.4, 114.3, 68.2, 54.2, 51.6, 45.4, 29.5.

MS (ESI) 492 (M + H<sup>+</sup>).

### Example 3

#### 10 2-(3-chlorophenoxy)-N-(1-([1-(4-methoxyphenyl)-1*H*-pyrrol-3-yl)methyl]piperidin-4-yl)acetamide

The residue after workup was purified on silica gel eluting with DCM:MeOH (95:5). The relevant fractions were concentrated, triturated with Et<sub>2</sub>O and subsequently dried to give 0.26 g (48%) of the title compound.

15 <sup>1</sup>H NMR (MeOD-d<sub>4</sub>) δ 7.32-7.38 (m, 2H), 7.26 (m, 1H), 6.95-7.06 (m, 6H), 6.91 (dd, 1H), 6.25 (m, 1H), 4.50 (s, 2H), 3.81 (s, 3H), 3.79 (m, 1H), 3.48 (s, 2H), 2.98 (m, 2H), 2.17 (m, 2H), 1.87 (m, 2H), 1.53-1.68 (m, 2H).

<sup>13</sup>C NMR (MeOD-d<sub>4</sub>) δ 169.9, 160.0, 159.1, 136.0, 135.6, 131.7, 122.8, 122.5, 121.2, 120.6, 116.5, 115.8, 114.3, 112.6, 68.3, 56.0, 52.9, 47.9, 31.9.

20 MS (ESI) 454 (M + H<sup>+</sup>).

### Example 4

#### 2-(3-chlorophenoxy)-N-(1-([1-(2-chlorophenyl)-1*H*-pyrrol-3-yl)methyl]piperidin-4-yl)acetamide

25 The residue after work-up was purified on silica gel eluting with DCM:MeOH (95:5) to give 0.20 g (64%) of the title compound.

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>) δ 7.97-7.99 (m, 1H), 7.62-7.64 (m, 1H), 7.37-7.51 (m, 3H), 7.29-7.34 (m, 1H), 7.00-7.04 (m, 2H), 6.89-6.92 (m, 3H), 6.18 (s br, 1H), 4.49 (s, 2H), 3.63 (m, 1H), 3.32 (s, 2H), 2.87 (m, 2H), 1.99 (m, 2H), 1.70 (m, 2H), 1.48-1.55 (m, 2H). MS (ESI)

30 458 (M + H<sup>+</sup>).

### Example 5

**2-(3-chlorophenoxy)-N-[1-([1-[5-(trifluoromethyl)pyridin-2-yl]-1H-pyrrol-3-yl)methyl]piperidin-4-yl]acetamide**

The residue after work-up was purified on silica gel eluting with first DCM:MeOH (98:2) followed by DCM:MeOH (95:5), concentrated, triturated with Et<sub>2</sub>O and subsequently dried to give 0.29 g (63%) of the title compound as a brown solid.

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.67 (br s, 1H), 7.95 (m, 1H), 7.45-7.51 (m, 2H), 7.36 (d, 1H), 7.25 (m, 1H), 7.02 (br d, 1H), 6.94 (br s, 1H), 6.81 (m, 1H), 6.34-6.42 (m, 2H), 4.46 (s, 2H), 3.91 (m, 1H), 3.46 (s, 2H), 2.90 (m, 2H), 2.18 (m, 2H), 1.96 (m, 2H), 1.48-1.62 (m, 2H).

<sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 166.9, 157.9, 153.3, 146.3 (q, *J* = 4 Hz), 135.9 (q, *J* = 3 Hz), 135.3, 130.7, 123.7 (q, *J* = 271 Hz), 122.7 (q, *J* = 33 Hz), 122.6, 118.6, 117.6, 115.6, 114.0, 112.9, 110.4, 67.6, 55.2, 52.0, 46.3, 32.0.

MS (ESI) 493 (M + H<sup>+</sup>).

**Example 6**

**2-(3-chlorophenoxy)-N-(1-([1-(3-chlorophenyl)-1H-pyrrol-3-yl]methyl)piperidin-4-yl)acetamide**

The residue after work-up was purified on silica gel eluting with first DCM:MeOH (98:2) followed by DCM:MeOH (95:5), concentrated, triturated with Et<sub>2</sub>O and subsequently dried to give 0.30 g (70%) of the title compound as an off-white, semisolid material.

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.14-7.36 (m, 5H), 6.91-7.02 (m, 4H), 6.79 (m, 1H), 6.42 (br d, 1H), 6.28 (m, 1H), 4.43 (s, 2H), 3.90 (m, 1H), 3.45 (s, 2H), 2.88 (m, 2H), 2.15 (m, 2H), 1.94 (m, 2H), 1.47-1.60 (m, 2H).

<sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 166.8, 157.8, 141.5, 135.2, 135.1, 130.5, 125.3, 122.8, 122.3, 120.1, 120.6, 119.0, 118.3, 117.9, 115.5, 112.8, 112.4, 67.4, 55.2, 51.8, 46.2, 32.0. MS (ESI) 458 (M + H<sup>+</sup>).

**Example 7**

**2-(3-chlorophenoxy)-N-[1-(4-pyridin-2-ylbenzyl)piperidin-4-yl]acetamide**

2-(3-chlorophenoxy)-N-piperidin-4-ylacetamide (60.0 mg, 0.223 mmol) and 4-pyridin-2-ylbenzaldehyde (49.0 mg, 0.268 mmol) were dissolved in 4 mL of DCM. NaBH(OAc)<sub>3</sub> (85.0 mg, 0.402 mmol) was added and the mixture was stirred at room temperature for about 12 h. A saturated aqueous solution of NH<sub>4</sub>Ac (10 mL) was added and the mixture

was extracted with EtOAc. The combined organic phase was washed with water, dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. Automated HPLC purification gave the pure title compound as a solid (50 mg, 51%).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.65 (m, 1H), 7.91 (d, 2H), 7.70 (m, 2H), 7.38 (d, 2H), 7.20 (m, 2H), 6.98 (d, 1H), 6.91 (s, 1H), 6.77 (m, 1H), 6.40 (d, 1H), 4.42 (s, 2H), 3.89 (m, 1H), 3.52 (s, 2H), 2.79 (m, 2H), 2.14 (t, 2H), 1.92 (m, 2H), 1.51 (m, 2H).

<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 167.0, 158.0, 157.5, 149.8, 139.6, 138.5, 136.9, 135.4, 130.8, 129.6, 127.0, 122.6, 122.2, 120.6, 115.7, 113.0, 67.7, 62.8, 52.3, 46.5, 32.3.

LC-MS [M+H]<sup>+</sup> 436.1, [M]<sup>-</sup> 434.1

Using the synthetic and purification methods described in Example 7, the compounds of Examples 8-13 were similarly prepared from 2-(3-chlorophenoxy)-N-piperidin-4-ylacetamide and the appropriate aldehyde:

#### Example 8

##### 2-(3-chlorophenoxy)-N-(1-([5-(4-chlorophenyl)-2-furyl]methyl)piperidin-4-yl)acetamide

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.56 (m, 2H), 7.31 (m, 2H), 7.21 (t, 1H), 6.99 (d, 1H), 6.91 (m, 1H), 6.77 (dd, 1H), 6.56 (d, 1H), 6.35 (d, 1H), 6.26 (d, 1H), 4.43 (s, 2H), 3.87 (m, 1H), 3.58 (s, 2H), 2.86 (m, 2H), 2.24 (t, 2H), 1.93 (m, 2H), 1.54 (m, 2H).

<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 167.0, 158.0, 152.6, 152.1, 135.4, 133.0, 130.8, 129.6, 129.0, 125.1, 122.6, 115.7, 113.0, 111.2, 106.3, 67.7, 55.1, 51.9, 46.2, 32.2.

LC-MS [M+H]<sup>+</sup> 459.1; [M]<sup>-</sup> 457.0.

#### Example 9

##### 2-(3-chlorophenoxy)-N-[1-([1-[4-(trifluoromethoxy)phenyl]-1H-pyrrol-3-yl]methyl)piperidin-4-yl]acetamide

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.36 (m, 2H), 7.26 (m, 2H), 7.21 (t, 1H), 6.96-7.02 (m, 3H), 6.93 (m, 1H), 6.79 (m, 1H), 6.47 (d, 1H), 6.28 (m, 1H), 4.43 (s, 2H), 3.92 (m, 1H), 3.54 (s, 2H), 2.98 (m, 2H), 2.23 (m, 2H), 1.94 (m, 2H), 1.62 (m, 2H).

<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 167.1, 158.0, 146.8, 139.3, 135.4, 130.8, 122.6, 122.0, 122.5, 121.5, 121.3, 119.6, 119.3, 115.7, 113.1, 112.8, 67.6, 54.8, 51.6, 46.2, 31.6.

LC-MS  $[M+H]^+$  508.1;  $[M]^-$  506.0.

#### Example 10

##### 2-(3-chlorophenoxy)-N-[1-[3-(1H-pyrrol-1-yl)benzyl]piperidin-4-yl]acetamide

5  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.40-7.15 (m, 5H), 7.11 (m, 2H), 7.02 (m, 1H), 6.95 (t, 1H), 6.81 (m, 1H), 6.38 (bd, 1H), 6.35 (t, 2H), 4.46 (s, 2H), 3.93 (m, 1H), 3.53 (s, 2H), 2.82 (m, 2H), 2.18 (m, 2H), 1.94 (m, 2H), 1.53 (m, 2H).

$^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  167.0, 158.0, 141.0, 140.6, 135.5, 130.8, 129.6, 126.3, 122.7, 121.0, 119.5, 119.4, 115.8, 113.0, 110.6, 67.7, 62.9, 52.4, 46.5, 32.4.

10 LC-MS  $[M+H]^+$  424.2;  $[M]^-$  422.1

#### Example 11

##### 2-(3-chlorophenoxy)-N-[1-(3-pyridin-2-ylbenzyl)piperidin-4-yl]acetamide

15  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.67 (m, 1H), 7.93 (s, 1H), 7.85 (m, 1H), 7.73 (m, 2H), 7.40 (m, 2H), 7.22 (m, 2H), 7.00 (m, 1H), 6.92 (t, 1H), 6.78 (dd, 1H), 6.39 (d, 1H), 4.43 (s, 2H), 3.91 (m, 1H), 3.57 (s, 2H), 2.83 (m, 2H), 2.18 (m, 2H), 1.92 (m, 2H), 1.52 (m, 2H).

$^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  167.0, 158.0, 157.7, 149.9, 139.6, 139.2, 136.9, 135.5, 130.8, 129.9, 128.9, 127.9, 126.0, 122.6, 122.3, 120.9, 115.7, 113.0, 67.9, 63.2, 52.3, 46.5, 32.3.

20 LC-MS  $[M+H]^+$  436.2;  $[M]^-$  434.1

#### Example 12

##### 2-(3-chlorophenoxy)-N-(1-([5-(2,4-dichlorophenyl)-2-furyl]methyl)piperidin-4-yl)acetamide

25  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.77 (d, 1H), 7.43 (d, 1H), 7.27 (dd, 1H), 7.22 (d, 1H), 7.05 (d, 1H), 7.00 (m, 1H), 6.92 (m, 1H), 6.78 (dd, 1H), 6.35 (d, 1H), 6.32 (d, 1H), 4.44 (s, 2H), 3.88 (m, 1H), 3.61 (s, 2H), 2.87 (m, 2H), 2.25 (m, 2H), 1.95 (m, 2H), 1.54 (m, 2H).

$^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  167.1, 158.0, 152.2, 149.0, 135.5, 133.0, 130.8, 130.6, 128.8, 128.0, 127.4, 122.7, 115.7, 113.0, 112.2, 111.2, 67.7, 55.0, 52.0, 46.2, 32.2.

30 LC-MS  $[M+H]^+$  495.0;  $[M]^-$  492.9.

#### Example 13

**2-(3-chlorophenoxy)-N-[1-({5-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]-2-thienyl)methyl}piperidin-4-yl]acetamide**

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.24 (dd, 1H), 7.01 (m, 2H), 6.92 (m, 2H), 6.80 (dd, 1H), 6.59 (s, 1H), 6.39 (d, 1H), 4.45 (s, 2H), 4.00 (s, 3H), 3.92 (m, 1H), 3.71 (s, 2H), 2.89 (m, 2H), 2.22 (m, 2H), 1.93 (m, 2H), 1.54 (m, 2H).

<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 167.1, 158.0, 145.6, 138.8, 135.5, 130.8, 129.1, 127.5, 126.3, 122.7, 115.7, 113.0, 104.8, 67.7, 57.3, 52.3, 46.3, 38.7, 32.3

LC-MS [M+H]<sup>+</sup> 513.1; [M]<sup>-</sup> 511.0.

**Example 14**

**N-(1-([1-(4-bromophenyl)-1H-pyrrol-3-yl]methyl)piperidin-4-yl)-2-(3-chlorophenoxy)acetamide**

2-(3-chlorophenoxy)-N-piperidin-4-ylacetamide (53.7 mg, 0.200 mmol) was dissolved in MeOH (0.67 ml), 1-(4-bromophenyl)-1H-pyrrole-3-carbaldehyde (75 mg, 0.300 mmol) dissolved in DCM (3 ml) and acetic acid (0.1 ml) was added to a process vial charged with polymer-supported cyanoborohydride (93 mg, 4.3 mmol/g, Nova Biochem). The mixture was heated to 140°C for 15 minutes in a microwave oven. After filtration PS-Isocyanate (50 mg, 0.07 mmol, Argonaut) and PS-Trisamine (50 mg, 0.22 mmol, Argonaut) was added to scavenge unreacted material. Filtration, evaporation automated HPLC purification gave the title compound.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.52 (m, 2H), 7.24 (m, 3H), 6.92-7.04 (m, 4H), 6.79 (dd, 1H), 6.34 (m, 1H); 6.27 (dd, 1H), 4.44 (s, 2H), 3.90 (m, 1H), 3.44 (s, 2H), 2.89 (d, 2H), 2.15 (dd, 2H), 1.94 (d, 2H), 1.52 (m, 2H).

LC-MS [M+H]<sup>+</sup> 502.5, 504.5; [M]<sup>-</sup> 500.8, 502.8

**Example 15**

**2-(3-chlorophenoxy)-N-methyl-N-[1-({1-[4-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide**

**i) N-(1-benzylpiperidin-4-yl)-2-chloro-N-methylacetamide**

Chloroacetyl chloride (1.1 mL, 14 mmol) was added dropwise to a stirred solution of 1-benzyl-N-methylpiperidin-4-amine (2.5 g, 12 mmol, prepared as described by Russell, M.

G. N. *et al. J. Med. Chem.*, **1999**, *42*, 4981) in DCM (50 mL) at 0 °C. The mixture was stirred for 1 h at rt. whereupon additional DCM (100 mL) was added and the organic phase was washed with NaHCO<sub>3</sub> (50 mL, aq., sat.), dried over MgSO<sub>4</sub> and concentrated to give 3.4 g (quant.) of the title compound as a thick slightly yellow oil which was used in the next step without further purification.

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, complex rotameric mixture, \* denotes minor rotamer peaks) δ 7.20-7.38 (m, 5H), 4.40\* (s, 2H), 4.35 (s, 2H), 4.18 (m, 1H), 3.58\* (m, 1H), 3.48\* (s, 2H), 3.47 (s, 2H), 2.88 (br s, 1H), 2.84 (s, 3H), 2.72\* (s, 3H), 1.95-2.12 (m, 2H), 1.56-1.84 (m, 3H), 1.43 (m, 2H).

MS (ESI) 281.3 (M + H<sup>+</sup>).

**ii) *N*-(1-benzylpiperidin-4-yl)-2-(3-chlorophenoxy)-*N*-methylacetamide**

Potassium *tert*-butoxide (1.05 g, 9.3 mmol) was added portionwise to a solution of 3-chlorophenol (1.2 g, 9.3 mmol) in THF (15 mL) and the mixture was stirred until a clear solution was obtained. *N*-(1-benzylpiperidin-4-yl)-2-chloro-*N*-methylacetamide (1.5 g, 5.3 mmol) dissolved in THF (15 mL) was added dropwise and the mixture was stirred for 1.5 h. Water (10 mL) was added and the mixture was extracted with EtOAc (2 x 50 mL) and the combined organic phases were washed with 1 M NaOH (2 x 20 mL). The organic phase was concentrated and the residue was purified on silica gel eluted with DCM:MeOH (95:5) to give 2.0 g (quant) of the title compound as a off-white solid.

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, complex rotameric mixture, \* denotes minor rotamer peaks) δ 7.20-7.36 (m, 6H), 6.95-7.03 (m, 2H), 6.87 (br d, 1 H), 4.90\* (s, 2H), 4.84 (s, 2H), 4.19 (m, 1H), 3.55\* (m, 1H), 3.47\* (s, 2H), 3.45 (s, 2H), 2.87 (br s, 1H), 2.84 (s, 3H), 2.72\* (s, 3H), 1.93-2.08 (m, 2H), 1.58-1.84 (m, 3H), 1.42 (m, 2H).

MS (ESI) 373.3 (M + H<sup>+</sup>).

**iii) 2-(3-chlorophenoxy)-*N*-methyl-*N*-piperidin-4-ylacetamide**

1-Chloroethyl chloroformate (1.2 g, 8.4 mmol) was added to a solution of *N*-(1-benzylpiperidin-4-yl)-2-(3-chlorophenoxy)-*N*-methylacetamide (4.1 g, 11.4 mmol) in dichloroethane (30 mL) and the mixture was heated at reflux for 2.5 h. The reaction mixture was concentrated and methanol (30 mL) was added and heated to reflux until for 1 h (overnight). The reaction mixture was concentrated and the residue was dissolved in HCl diluted

with water (50 mL) and extracted with Et<sub>2</sub>O (2 x 25 mL). The aqueous phase was made basic with NaOH and extracted with EtOAc (2 x 50 mL). The combined organic phases were concentrated and the residue was purified on silica gel eluted with first DCM:MeOH (9:1) followed by DCM:MeOH (8:2) containing 1% NH<sub>3</sub> (aq.) and finally with DCM:MeOH (7:3) containing 1% TEA, to give 0.82 g (65%) of the title compound after drying.

<sup>1</sup>H NMR (MeOD-d<sub>4</sub>, complex rotameric mixture, \* denotes minor rotamer peaks) δ 7.21-7.29 (m, 1H), 6.86-7.03 (m, 3H), 4.86\* (s, 2 H), 4.81 (s, 2H), 4.45 (m, 1H), 3.81\* (m, 1H), 3.11 (m, 2H), 2.96 (s, 3H), 2.86\* (s, 3H), 2.61-2.73 (m, 2H), 1.56-1.86 (m, 4H). MS (ESI) 283.2 (M + H<sup>+</sup>).

**iv) 2-(3-chlorophenoxy)-N-methyl-N-[1-({1-[4-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide**

2-(3-chlorophenoxy)-N-methyl-N-piperidin-4-ylacetamide (0.40 g, 1.4 mmol) and 1-[4-(trifluoromethyl)phenyl]-1H-pyrrole-3-carbaldehyde (0.34 g, 1.4 mmol) was dissolved in dichloroethane (20 mL). Sodium triacetoxyborohydride (0.42 g, 1.4 mmol) was added and the mixture was stirred at rt. for 16 h (over night). NaHCO<sub>3</sub> (10 mL, aq., sat.) was added and the aqueous phase was extracted with DCM (2 x 20 mL). The combined organic phases were concentrated and the residue was purified on silica gel eluting with DCM:MeOH (98:2) followed by DCM:MeOH (95:5) to give 0.56 g (79%) of the title compound as a off-white solid.

<sup>1</sup>H NMR (MeOD-d<sub>4</sub>, complex rotameric mixture, \* denotes minor rotamer peaks) δ 7.73 (d, 2H), 7.66 (d, 2H), 7.20-7.31 (m, 3H), 6.93-7.00 (m, 2H), 6.86-6.91 (m, 1H), 6.36 (br s, 1H), 4.84\* (s, 2H), 4.80 (s, 2H), 4.37 (m, 1H), 3.71\* (m, 1H), 3.51 (s, 2H), 3.10 (m, 2H), 2.95 (s, 3H), 2.86\* (s, 3H), 2.10-2.24 (m, 2H), 1.58-2.03 (m, 4 H).

<sup>13</sup>C NMR (MeOD-d<sub>4</sub>, complex rotameric mixture, \* denotes minor rotamer peaks) δ 169.9\*, 169.8, 160.5, 160.0\*, 144.5, 136.0\*, 135.9, 131.6\*, 131.5, 128.0 (q, J = 4 Hz), 128.0 (q, J = 33 Hz), 125.8 (q, J = 271 Hz), 123.2, 122.6\*, 122.5, 120.4, 120.3, 120.1, 120.0\*, 116.3, 116.1\*, 114.4, 114.1\*, 68.1\*, 67.7, 55.7, 55.6\*, 53.4, 53.2, 52.9, 30.1, 29.1, 28.9, 28.1\*.

MS (ESI) 506.3 (M + H<sup>+</sup>).

**Example 16****2-[(3-chlorophenyl)thio]-N-[1-({1-[4-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl)methyl}piperidin-4-yl]acetamide****i) N-(1-benzylpiperidin-4-yl)-2-[(3-chlorophenyl)thio]acetamide**

Potassium *tert*-butoxide (1.26 g, 11.3 mmol) was added portionwise to a solution of 3-chlorothiophenol (1.8 g, 12.4 mmol) in THF (20 mL) and the mixture was stirred until a clear solution was obtained. *N*-(1-benzylpiperidin-4-yl)-2-chloroacetamide (3 g, 11.3 mmol) dissolved in THF (25 mL) was added dropwise and the mixture was stirred over night at rt. HPLC indicated that starting material was consumed. The solvent was removed by evaporation and the residue was purified on silica gel eluted with DCM:MeOH (95:5) to give 2.35 g (57%) of the title compound.

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.10-7.29 (m, 9H), 6.58 (d br, 1H), 3.77 (m, 1H), 3.59 (s, 2H), 3.43 (s, 2H), 2.66 (m, 2H), 2.08 (m, 2H), 1.77 (m, 2H), 1.38 (m, 2H).

MS (ESI) 375.2 (M + H<sup>+</sup>).

**ii) 2-[(3-chlorophenyl)thio]-N-piperidin-4-ylacetamide**

1-Chloroethyl chloroformate (1.1 g, 6.7 mmol) was added to a solution of *N*-(1-benzylpiperidin-4-yl)-2-[(3-chlorophenyl)thio]acetamide (1.9 g, 5.1 mmol) in dichloroethane (30 mL) and the mixture was stirred first at rt. for 1 h and then heated at reflux for 1 h. The reaction mixture was concentrated and methanol (30 mL) was added and heated to reflux for 1 h and then stirred at rt. over night. The reaction mixture was concentrated and the residue was dissolved in toluene and evaporated to dryness. The resulting residue was diluted with DCM and washed with 5 M NaOH (aq.). The organic layer was separated and concentrated and the residue was purified on silica gel eluted with first DCM:MeOH (8:2) followed by DCM:MeOH (8:2) containing 0.5% NH<sub>3</sub> (25% aq.) and then pure MeOH to give 0.30 g (21%) of the title compound.

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.09-7.30 (m, 4H), 6.58 (br d, 1H), 3.86 (m, 1H), 3.60 (s, 2H), 2.98 (m, 2H), 2.55-2.76 (m, 2H), 1.81 (m, 2H), 1.64 (br s, 1H) 1.14-1.34 (m, 2H).

MS (ESI) 286.2 (M + H<sup>+</sup>).



iii) 2-[(3-chlorophenyl)thio]-*N*-[1-([1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl)methyl]piperidin-4-yl]acetamide

2-[(3-Chlorophenyl)thio]-*N*-piperidin-4-ylacetamide (0.30 g, 1.1 mmol) and 1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrole-3-carbaldehyde (0.25 g, 1.1 mmol) was dissolved in dichloroethane (7 mL). Sodium triacetoxyborohydride (0.31 g, 1.5 mmol) was added and the mixture was stirred at rt. for 3 h and 45 min. Sat. aq. NaHCO<sub>3</sub> (11 mL) was added and the aqueous phase was extracted with DCM. The organic layer was separated and dried over Mg<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was purified on silica gel eluting with DCM:MeOH (95:5) to give 0.25 g (47%) of the title compound.

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.61-7.72 (m, 2H), 7.41-7.51 (m, 2H), 7.10-7.30 (m, 4H), 6.99-7.10 (m, 2H), 6.58-6.61 (br d, 1H), 6.31 (m, 1H), 3.72-3.89 (m, 1H), 3.61 (s, 2H), 3.45 (s, 2H), 2.75-2.91 (m, 2H), 2.09-2.27 (m, 2H), 1.76-1.92 (m, 2H), 1.36-1.59 (m, 2H).

<sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 143.1, 136.7, 135.2, 130.4, 128.0, 127.4 (q, *J* = 33 Hz), 127.0 (q, *J* = 3 Hz), 127.0, 126.2, 124.1 (q, *J* = 271 Hz), 122.7, 119.7, 119.2, 118.6, 113.1, 55.2, 51.8, 46.7, 37.3, 31.7.

MS (ESI) 508.2 (M + H<sup>+</sup>).

**Example 17**

2-(3-chlorophenoxy)-*N*-(1-([1-(4-cyanophenyl)-1*H*-pyrrol-3-yl)methyl]piperidin-4-yl)acetamide

2-(3-chlorophenoxy)-*N*-piperidin-4-ylacetamide (1eq, 0.279 mmol) and 4-(3-formyl-1*H*-pyrrol-1-yl)benzonitrile (1.2 eq) were dissolved in DCM (5 ml) and left to stir for 5-10 minutes. MP-BH(OAc)<sub>3</sub> (2.5 meq) was added and the reaction stirred for a further 3h at ambient temperature. The reaction was filtered, washed through with DCM (2 ml) and the filtrate concentrated in vacuo. Flash silica chromatography on a 9g or 40g Biotage cartridge eluting with EtOAc/MeOH/TEA (100/2/0.2) yielded the product as a white foam (81mg, 65%).

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.67 (d, 2H), 7.43 (d, 2H), 7.22 (t, 1H), 6.77-7.08 (m, 5H), 6.32-6.38 (m, 2H), 4.43 (s, 2H), 3.89 (m, 1H), 3.42 (s, 2H), 2.86 (d, 2H), 2.13 (t, 2H), 1.92 (m, 2H), 1.50 (m, 2H).

<sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 167.0, 158.0, 143.7, 135.4, 134.0, 130.8, 124.5, 122.6, 119.7, 119.0, 118.7, 118.1, 115.8, 113.8, 113.0, 108.5, 67.7, 55.4, 52.2, 46.5, 32.3.

MS (ESI): 449.3 (M+H<sup>+</sup>)

This method used in the preparation of the compound of Example 17, with minor variations, was used on a 0.1-1 mmol scale for the synthesis of the compounds of Examples 18-26.

#### Example 18

**2-(pyridin-3-yloxy)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl)methyl}piperidin-4-yl]acetamide.**

<sup>1</sup>HNMR (CDCl<sub>3</sub>) δ 8.32 (d, 1H), 8.26 (dd, 1H), 7.62 (d, 2H), 7.42 (d, 2H), 7.16-7.26 (m, 2H), 7.02 (m, 2H), 6.43 (d, 1H), 6.29 (m, 1H), 4.47 (s, 2H), 3.85-3.92 (m, 1H), 3.42 (s, 2H), 2.87 (d, 2H), 2.12 (t, 2H), 1.93 (d, 2H), 1.47-1.57 (m, 2H).

MS (ESI): 459.2 (M+H<sup>+</sup>)

#### Example 19

**2-[3-(trifluoromethoxy)phenoxy]-N-[1-({1-[4-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl)methyl}piperidin-4-yl]acetamide**

<sup>1</sup>HNMR (CDCl<sub>3</sub>) δ 7.63 (d, 2H), 7.43 (d, 2H), 7.30 (t, 1H), 7.04 (m, 2H), 6.78-6.89 (m, 3H), 6.38 (d, 1H), 6.30 (m, 1H), 4.45 (s, 2H), 3.85-3.94 (m, 1H), 3.43 (s, 2H), 2.87 (d, 2H), 2.14 (t, 2H), 1.93 (d, 2H), 1.48-1.57 (m, 2H).

<sup>13</sup>CNMR (CDCl<sub>3</sub>): δ 166.8, 158.3, 150.4, 143.2, 130.8, 126 (q, 257), 12.4 (q, J=33.8), 127.1 (q, J=3.4), 124.4 (q, J=270), 123.8, 119.6, 119.3, 118.3, 114.6, 113.1, 113.0, 108.4, 67.8, 55.4, 52.2, 46.5, 32.3

MS (ESI): 542.4 (M+H<sup>+</sup>)

#### Example 20

**2-[3-(trifluoromethoxy)phenoxy]-N-[1-({1-[5-(trifluoromethyl)pyridin-2-yl]-1H-pyrrol-3-yl)methyl}piperidin-4-yl]acetamide**

<sup>1</sup>HNMR (CDCl<sub>3</sub>) δ 8.62 (s, 1H), 7.90 (dd, 1H), 7.47 (t, 1H), 7.42 (s, 1H), 7.32-7.29 (m, 2H), 6.77-6.88 (m, 3H), 6.37 (d, 1H), 6.32 (m, 1H), 4.44 (s, 2H), 3.85-3.92 (m, 1H), 3.42 (s, 2H), 2.85 (d, 2H), 2.14 (t, 2H), 1.92 (d, 2H), 1.47-1.56 (m, 2H).

MS (ESI): 543.4 (M+H<sup>+</sup>)

**Example 21**

**2-(3-cyanophenoxy)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide**

<sup>1</sup>HNMR (CDCl<sub>3</sub>) δ 7.65 (d, 2H), 7.45 (m, 3H), 7.35 (d, 1H), 7.22 (m, 2H), 7.05 (d, 2H), 6.35 (m, 2H), 4.44 (s, 2H), 3.86-3.98 (m, 1H), 3.64 (s, 2H), 2.90 (d, 2H), 2.18 (t, 2H), 1.95 (m, 2H), 1.55 (m, 2H).

<sup>13</sup>CNMR (CDCl<sub>3</sub>): δ 166.4, 157.4, 143.2, 131.0, 127.4 (q, J=32.7), 127.1 (q, J=3.6), 126.1, 124.3 (q, J=271), 123.6, 119.7, 119.6, 119.2, 118.5, 118.4, 113.9, 113.1, 67.7, 55.4, 52.2, 46.6, 32.3.

MS (ESI): 483.2 (M+H<sup>+</sup>)

**Example 22**

**2-(3-fluorophenoxy)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide**

<sup>1</sup>HNMR (CDCl<sub>3</sub>) δ 7.65 (d, 2H), 7.45 (d, 2H), 7.25 (dd, 1H), 7.05 (d, 2H), 6.6-6.8 (m, 3H), 6.4 (br.d, 1H), 6.30 (s, 1H), 4.44 (s, 2H), 3.84-3.93 (m, 1H), 3.64 (s, 2H), 2.90 (d, 2H), 2.15 (t, 2H), 1.95 (m, 2H), 1.55 (m, 2H).

<sup>13</sup>CNMR (CDCl<sub>3</sub>): δ 167.1, 163.8 (d, J=246), 158.6 (d, J=11.3), 143.2, 130.8 (d, J=10.1), 127.4 (q, J=33.8), 127.1 (q, J=3.4), 124.4 (q, J=270), 123.7, 119.7, 119.2, 118.4, 113.1, 110.4, 109.3 (d, J=22.7), 103.1 (d, J=22.7), 67.7, 55.4, 52.1, 46.5, 32.3.

MS (ESI): 476.2 (M+H<sup>+</sup>)

**Example 23**

**2-(3-cyanophenoxy)-N-[1-({5-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]-2-thienyl}methyl)piperidin-4-yl]acetamide**

<sup>1</sup>HNMR (CDCl<sub>3</sub>) δ 7.42 (t, 1H), 7.32 (d, 1H), 7.15 (m, 2H), 7.05 (d, 1H), 6.9 (d, 1H), 6.6 (s, 1H), 6.38 (br.d, 1H), 4.48 (s, 2H), 4.0 (s, 3H), 3.90-3.98 (m, 1H), 3.70 (s, 2H), 2.90 (d, 2H), 2.25 (t, 2H), 1.95 (m, 2H), 1.55 (m, 2H).

MS (ESI): 504.2 (M+H<sup>+</sup>)

**Example 24**

**2-(2-chlorophenoxy)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide**

<sup>1</sup>HNMR (CDCl<sub>3</sub>) δ 7.65 (d, 2H), 7.45 (d, 2H), 7.40 (d, 1H), 7.25 (t, 1H), 7.05 (d, 2H), 6.95 (t, 1H), 6.8-6.9 (m, 2H), 6.35 (s, 1H), 4.48 (s, 2H), 3.84-3.93 (m, 1H), 3.62 (s, 2H), 2.78 (d, 2H), 2.25 (t, 2H), 1.95 (m, 2H), 1.60 (m, 2H).

<sup>13</sup>CNMR (CDCl<sub>3</sub>): δ 166.9, 153.0, 143.2, 130.6, 128.3, 127.4 (q, J=33.8), 127.1 (q, J=3.6), 124.3 (q, J=27.1), 123.7, 123.1, 123.0, 119.7, 119.2, 118.4, 114.1, 113.2, 68.2, 55.5, 52.0, 46.1, 32.3

MS (ESI): 492.3 (M+H<sup>+</sup>)

**Example 25**

**2-(3-chlorophenoxy)-N-[1-({5-[4-(trifluoromethoxy)phenyl]-2-furyl}methyl)piperidin-4-yl]acetamide**

<sup>1</sup>HNMR (CDCl<sub>3</sub>) δ 7.65 (d, 2H), 7.21 (m, 3H), 7.00 (m, 1H), 6.92 (t, 1H), 6.78 (dd, 1H), 6.57 (d, 1H), 6.35 (d, 1H), 6.27 (d, 1H), 4.43 (s, 2H), 3.84-3.92 (m, 1H), 3.59 (s, 2H), 2.86 (d, 2H), 2.24 (t, 2H), 1.94 (d, 2H), 1.49-1.58 (m, 2H).

<sup>13</sup>CNMR (CDCl<sub>3</sub>): δ 167.0, 158.0, 152.4, 152.3, 148.3, 135.5, 130.8, 129.9, 125.2, 122.6, 121.4, 120.6 (q, J=258), 115.7, 113.0, 111.2, 106.5, 67.7, 55.1, 51.9, 46.2, 32.2

MS (ESI): 509.2 (M+H<sup>+</sup>)

**Example 26**

**2-(3-chlorophenoxy)-N-(1-({1-(5-chloropyrimidin-2-yl)-1H-pyrrol-3-yl}methyl)piperidin-4-yl)acetamide**

<sup>1</sup>HNMR (CDCl<sub>3</sub>) δ 8.5 (s, 1H), 7.63 (m, 1H), 7.55 (m, 1H), 7.2 (dd, 1H), 6.95 (d, 1H), 6.90 (t, 1H), 6.77 (dd, 1H), 6.36 (br.d, 1H), 6.27 (m, 1H), 4.42 (s, 2H), 3.84-3.93 (m, 1H), 3.4 (s, 2H), 2.85 (d, 2H), 2.15 (t, 2H), 1.95 (m, 2H), 1.50 (m, 2H).

MS (ESI): 460.1 (M+H<sup>+</sup>)

**Example 27**

**2-(3-cyanophenoxy)-N-[1-({1-[4-(trifluoromethoxy)phenyl]-1H-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide**

2-(3-cyanophenoxy)-*N*-piperidin-4-ylacetamide (1eq, 1.93 mmol) and 1-[4-(trifluoromethoxy)phenyl]-1*H*-pyrrole-3-carbaldehyde (1.2eq) were dissolved in DCM (3ml) and stirred for 10 minutes. NaBH(OAc)<sub>3</sub> (2.5 eq) was then added and the reaction stirred for 16h. To the reaction mixture was added 10% Na<sub>2</sub>CO<sub>3</sub> (aq) (3ml) shaken and  
5 filtered over a phase separator onto a 1g SCX-2 column. The phase separation was washed through with DCM (1ml) and the SCX-2 with DCM (5ml). The product was released from the cation exchanger with 2M NH<sub>3</sub> in MeOH (2.5ml) the filtrate collected and evaporated in vacuo. Flash chromatography on the Biotage 9g silica cartridge using isocratic EtOAc:MeOH:TEA (100:5:0.1) gave product in unsatisfactory purity. The compound was  
10 further purified by automated HPLC purification to yield the compound as its mono acetate salt (23 mg, 21%).

<sup>1</sup>HNMR (CDCl<sub>3</sub>) δ 7.70 (d, 1H), 7.42 (m, 2H), 7.33 (m, 1H), 7.28 (dd, 1H), 7.13-7.20 (m, 2H), 7.05 (d, 1H), 6.32 (m, 2H), 4.48 (s, 2H), 3.84-3.93 (m, 1H), 3.62 (s, 2H), 2.89 (d, 2H), 2.25 (t, 2H), 1.95 (m, 2H), 1.50-1.60 (m, 2H).

15 MS (ESI): 499.3 (M+H<sup>+</sup>)

This method was also utilised for the synthesis of the compound of Example 28:

#### Example 28

20 **2-(3-cyanophenoxy)-*N*-(1-([5-(2,4-dichlorophenyl)-2-furyl]methyl)piperidin-4-yl)acetamide**

<sup>1</sup>HNMR (CDCl<sub>3</sub>) δ 7.78 (d, 1H), 7.40-45 (m, 2H), 7.26-7.34 (m, 2H), 7.13-7.20 (m, 2H), 7.05 (d, 1H), 6.28-6.36 (m, 2H), 4.44 (s, 2H), 3.84-3.93 (m, 1H), 3.62 (s, 2H), 2.85 (d, 2H), 2.25 (t, 2H), 1.95 (m, 2H), 1.50-1.60 (m, 2H).

25 MS (ESI): 484.0 (M+H<sup>+</sup>)

#### Example 29

**3-(3-chlorophenyl)-*N*-[1-([1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl]methyl)piperidin-4-yl]propanamide**

30

i) ***tert*-butyl-[1-([1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl]methyl)-piperidin-4-yl]-carbamate**

1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrole-3-carbaldehyde (4.054 g, 16.95 mmol) and *tert*-butyl piperidin-4-ylcarbamate (3.564 g, 17.80 mmol) was suspended in DCM (35 mL). Sodium triacetoxyborohydride (7.184 g, 33.90 mmol) was added and stirred overnight at rt. The reaction mixture was quenched with sat. NH<sub>4</sub>Cl aq. solution (30 mL), extracted with DCM (3 x 40 mL), washed with brine (30 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and purified with Biotage Horizon Pioneer® HPFS using a silica cartridge and eluted with EtOAc:MeOH:TEA (gradient from 100:0:0 to 100:5:0.1) to give 6.12 g (85%) of the title compound as a white solid.

<sup>1</sup>HNMR (MeOD-*d*<sub>4</sub>) δ 7.77 (d, 2H), 7.71 (d, 2H), 7.51 (s, 1H), 7.40 (t, 1H), 6.48 (m, 1H), 4.08 (s, 2H), 3.55-3.58 (m, 1H), 3.38 (d, 2H), 2.84 (t, 2H), 2.08 (m, 2H), 1.72 (m, 2H), 1.43 (s, 9H).

MS (ESI) 424.3 (M + 1H<sup>+</sup>).

**ii) 1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-amine dihydrochloride**

*tert*-butyl-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]carbamate (6.119 g, 14.45 mmol) was dissolved in HCl 4 M in 1,4-dioxane (35 mL) and stirred at rt. for 1.5 hours. Diethyl ether (10 mL) was added to the suspension which was stirred for 1.5 hours. The precipitate was filtered off and was washed with diethyl ether (200 mL) and was then dried at reduced pressure over night to give 4.98 g (87%) of the title compound as a cream-coloured white solid.

<sup>1</sup>HNMR (MeOD-*d*<sub>4</sub>) δ 7.77 (m, 4H), 7.63 (s, 1H), 7.40 (t, 1H), 6.56 (s, 1H), 4.28 (s, 2H), 3.65-3.69 (m, 2H), 3.49 (m, 1H), 3.16 (t, 2H), 2.30 (m, 2H), 1.99-2.10 (m, 2H).

MS (ESI) 325.2 (M + 1H<sup>+</sup>).

**iii) 3-(3-chlorophenyl)-*N*-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]propanamide**

1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-amine dihydrochloride (0.050 g, 0.126 mmol) and 3-(3-chlorophenyl)propionic acid (0.028 g, 0.152 mmol) was dissolved in DMF (7 mL). DIPEA (0.077 mL, 0.445 mmol) was added followed by HATU (0.058 g, 0.153 mmol). The mixture was stirred for 3 hours at room

temperature. EtOAc (10 mL) was added and the reaction mixture was washed with 1% Na<sub>2</sub>CO<sub>3</sub> aq. solution (3 x 10 mL), dried (MgSO<sub>4</sub>), concentrated and purified with Biotage Horizon Pioneer® HPFS using a silica cartridge and eluted with EtOAc:MeOH:TEA (100:5:0,1) to give the title compound (51 mg, 83%).

<sup>1</sup>HNMR (MeOD-d<sub>4</sub>) δ 7.70 (d, 2H), 7.62 (d, 2H), 7.19-7.26 (m, 4H), 7.09-7.16 (m, 2H), 6.33 (bs, 1H), 3.57-3.65 (m, 1H), 3.45 (s, 2H), 2.85-2.91 (m, 4H), 2.43 (t, 2H), 2.12 (t, 2H), 1.76 (d, 2H), 1.38-1.47 (m, 2H).

MS (ESI) 490.2 (M + 1H<sup>+</sup>).

#### Example 30

**(2E)-3-(3-chlorophenyl)-N-[1-((1-[4-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl)methyl)piperidin-4-yl]acrylamide**

1-((1-[4-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl)methyl)piperidin-4-amine dihydrochloride (0.050 g, 0.126 mmol) and (2E)-3-(3-chlorophenyl)acrylic acid (0.028 g, 0.153) was dissolved in DMF (7 mL). DIPEA (0.077 mL, 0.445 mmol) was added followed by HATU (0.057 g, 0.153 mmol). The mixture was stirred for 3 hours at room temperature. EtOAc (10 mL) was added and the mixture was washed with 1% Na<sub>2</sub>CO<sub>3</sub> aq. solution (3 x 10 mL), dried (MgSO<sub>4</sub>), concentrated and purified with Biotage Horizon Pioneer® HPFS using a silica cartridge and eluted with EtOAc:MeOH:TEA (100:5:0,1) to give the title compound (55 mg, 89%) as a solid.

<sup>1</sup>HNMR (MeOD-d<sub>4</sub>) δ 7.70 (d, 2H), 7.62 (d, 2H), 7.53 (s, 1H), 7.41-7.47 (m, 2H), 7.32-7.33 (m, 2H), 7.25 (m, 2H), 6.59 (d, 1H), 6.34 (t, 1H), 3.74-3.82 (m, 1H), 3.49 (s, 2H), 2.99 (d, 2H), 2.19 (t, 2H), 1.91 (m, 2H), 1.54-1.64 (m, 2H).

MS (ESI) 488.1 (M + H<sup>+</sup>).

#### Example 31

**2-(3,5-difluorophenoxy)-N-[1-((1-[4-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl)methyl)piperidin-4-yl]acetamide**

i) **2-chloro-N-[1-((1-[4-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl)methyl)piperidin-4-yl]acetamide**

1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-amine dihydrochloride (2.00 g, 5.05 mmol) and anhydrous potassium carbonate (3.07 g, 22.2 mmol) was suspended in DCM:Water (1:1, 30 mL). Chloroacetic acid (0.788 g, 8.34 mmol) and EDAC (1.60 g, 8.34 mmol) were dissolved in DCM (15 mL), stirred for 5 min. and then added to the DCM:water suspension, and stirred vigorous for 2.5 hours. A mixture of chloroacetic acid (0.100 g, 1.0 mmol) and EDAC (0.213 g, 1.1 mmol) was dissolved in DCM and was added to the reaction mixture. The mixture was stirred vigorous for 4 hours. The water phase was removed with a phase separator and another mixture of chloroacetic acid (0.210 g, 2.2 mmol) and EDAC (0.426 g, 2.2 mmol), dissolved in DCM, was added to the organic phase. The mixture was stirred for another 2 hours, concentrated and purified with Biotage Horizon Pioneer® HPFS using a silica cartridge and eluted with EtOAc:MeOH:TEA (100:2:0.2) to give the title compound, (1.53 g, 76%) as a white solid. <sup>1</sup>HNMR (MeOD-*d*<sub>4</sub>) δ 7.72 (d, 2H), 7.65 (d, 2H), 7.27 (m, 2H), 6.35 (m, 1H), 3.98 (s, 2H), 3.65-3.72 (m, 1H), 3.49 (s, 2H), 3.0 (d, 2H), 2.17 (t, 2H), 1.87 (d, 2H), 1.52-1.62 (m, 2H). MS (ESI) 400.1 (M + 1H<sup>+</sup>).

**ii) 2-(3,5-difluorophenoxy)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide**

2-chloro-*N*-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide (0.350 g, 0.875 mmol) was dissolved in dry THF (5 mL). 3,5-difluorophenol (0.228 g, 1.751 mmol) and potassium tert-butoxide (0.196 g, 1.751 mmol) was dissolved in dry THF (5 mL) and stirred for 5 min. before adding it to the solution of 2-chloro-*N*-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide in THF. The reaction mixture was stirred at rt. over night and was then concentrated and dissolved in DCM (20 mL), washed with water (10 mL), concentrated again and purified with Biotage Horizon Pioneer® HPFS using a silica cartridge with gradient elution with EtOAc:MeOH:TEA (gradient from 100:0:0 to 100:2:0.2) to give the title compound in (218 mg, 51%) as a white solid. <sup>1</sup>HNMR (MeOD-*d*<sub>4</sub>) δ 7.67-7.69 (d, 2H), 7.59-7.61 (d, 2H), 7.22-7.24 (m, 2H), 6.57-6.61 (m, 2H), 6.49-6.55 (m, 1H), 6.32 (s, 1H), 4.47 (s, 2H), 3.72-3.79 (m, 1H), 3.43 (s, 2H), 2.94 (d, 2H), 2.10 (t, 2H), 1.83 (m, 2H), 1.55-1.64 (m, 2H).



<sup>13</sup>CNMR (MeOD-d<sub>4</sub>) δ 168.2, 164.0 (dd, J=16, 246), 160.1 (t, J=16), 143.3, 124.4 (q, J=270), 126.8 (q, J=3.9), 126.7 (q, J=32), 122.1, 119.2, 119.1, 118.9, 113.0, 98.6 (dd, J=31.9), 96.7 (t, J=27), 67.4, 54.8, 51.8, 46.8, 30.9.

MS (ESI) 494.1 (M + 1H<sup>+</sup>).

5

### Example 32

#### 2-(2,6-diisopropylphenoxy)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl)methyl}piperidin-4-yl]acetamide

2-chloro-N-[1-({1-[4-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl)methyl}piperidin-4-yl]acetamide (0.070 g, 0.175 mmol) was dissolved in dry THF (5 mL). 2,6-diisopropylphenol (0.062 g, 0.350 mmol) and potassium tert-butoxide (0.039 g, 0.350 mmol) was dissolved in dry THF (5 mL) and stirred for 5 min. before adding it to reaction mixture. The reaction mixture was stirred at 50°C for 30 min then at rt. over night and was then concentrated and purified with a Biotage Horizon Pioneer® HPFS using a silica cartridge with EtOAc:MeOH:TEA (gradient from 100:0:0 to 100:2:0.2) to give the title compound (59 mg, 63%), as a white solid.

15

<sup>1</sup>HNMR (MeOD-d<sub>4</sub>) δ 7.70 (d, 2H), 7.63 (d, 2H), 7.26 (d, 2H), 7.10 (s, 3H) 6.35 (m, 1H), 4.23 (s, 2H), 3.83-3.89 (m, 1H), 3.48 (s, 2H), 3.20-3.27 (m, 2H), 2.98 (d, 2H), 2.19 (t, 2H), 1.91 (d, 2H) 1.62-1.72 (m, 2H), 1.20 (d, 12H).

20

<sup>13</sup>CNMR (MeOD-d<sub>4</sub>) δ 169.2, 152.5, 143.4, 141.5, 126.9 (q, J=3.7), 126.8 (q, J=32), 125.4, 124.5 (q, J=270), 124.2, 122.1, 119.3, 119.1, 118.8, 113.0, 72.9, 54.7, 51.9, 46.5, 31.0, 26.6, 23.3. MS (ESI) 542.7 (M + 1H<sup>+</sup>).

25

Using the method described in Example 32, the compound of Example 33 was similarly prepared from 2-chloro-N-[1-({1-[4-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl)methyl}piperidin-4-yl]acetamide and 2-isopropylphenol:

### Example 33

#### 2-(3-isopropylphenoxy)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl)methyl}piperidin-4-yl]acetamide

30

<sup>1</sup>HNMR (MeOD-d<sub>4</sub>) δ 7.70 (d, 2H), 7.62 (d, 2H), 7.24 (m, 2H), 7.17 (t, 1H) 6.84 (m, 2H), 6.73-6.76 (m, 1H), 6.32 (m, 1H), 4.45 (s, 2H), 3.74-3.81 (m, 1H), 3.45 (s, 2H), 2.93 (d, 2H), 2.80-2.96 (m, 1H), 2.13 (t, 2H), 1.83 (d, 2H), 1.55-1.65 (m, 2H), 1.20 (d, 6H).

MS (ESI) 500.6 (M + 1H<sup>+</sup>).

5

#### Example 34

##### 2-(2-cyanophenoxy)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl)methyl}piperidin-4-yl]acetamide

2-chloro-N-[1-({1-[4-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl)methyl}piperidin-4-yl]acetamide (0.050 g, 0.125 mmol), 2-hydroxybenzonitrile (0.022 g, 0.188 mmol), anhydrous potassium carbonate (0.035 g, 0.250 mmol) and potassium iodide (0.010 g, 0.063 mmol) were dissolved in 2-butanone (5 mL) and the mixture was refluxed (70°C) overnight. The reactions mixture was allowed to cool to rt., and was then concentrated and dissolved in DCM (15 mL) and was washed with 1% Na<sub>2</sub>CO<sub>3</sub> aq. solution. The organic phase was dried concentrated and the purified with Biotage Horizon Pioneer® HPFS using a silica cartridge and eluted with EtOAc:MeOH:TEA (100:5:0,1) to give the title compound ( 37 mg, 62%) as a solid.

<sup>1</sup>HNMR (MeOD-d<sub>4</sub>) δ 7.70 (d, 2H), 7.58-7.65 (m, 4H), 7.25 (m, 2H) 7.07-7.13 (m, 2H), 6.34 (m, 1H), 4.65 (s, 2H), 3.75-3.83 (m, 1H), 3.47 (s, 2H) 2.92 (d, 2H), 2.20 (t, 2H), 1.90 (m, 2H), 1.59-1.62 (m, 2H).

MS (ESI) 483.4 (M + 1H<sup>+</sup>).

Using the method described in Example 34, the compound of Example 35 was similarly prepared from 2-chloro-N-[1-({1-[4-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl)methyl}piperidin-4-yl]acetamide and isoquinolin-5-ol:

#### Example 35

##### 2-(isoquinolin-5-yloxy)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl)methyl}piperidin-4-yl]acetamide

<sup>1</sup>HNMR (MeOD-d<sub>4</sub>) δ 9.2 (bs, 1H), 8.45 (bs, 1H), 8.23 (d, 1H), 7.66-7.76 (m, 5H), 7.59 (t, 1H), 7.33 (m, 2H), 7.16 (d, 1H), 6.40 (m, 1H), 4.76 (s, 2H), 3.91 (m, 1H), 3.73 (s, 2H), 3.16 (d, 2H), 2.51 (t, 2H), 1.99 (m, 2H), 1.67-1.78 (m, 2H).

MS (ESI) 509.2 (M + 1H<sup>+</sup>).

### Pharmacological Properties

#### 5      MCH1 receptor radioligand binding.

Assays were performed on membranes prepared from CHO-K1 cells expressing the human Melanin concentrating hormone receptor 1 (MCH1r). Assays were performed in a 96-well plate format in a final reaction volume of 200  $\mu$ l per well. Each well contained 6  $\mu$ g of membrane proteins diluted in binding buffer (50 mM Tris, 3 mM MgCl<sub>2</sub>, 0.05 % bovine  
10 serum albumin and the radioligand <sup>125</sup>I-MCH (IM344 Amersham) was added to give 10 000 cpm (counts per minute) per well. Each well contained 2  $\mu$ l of the appropriate concentration of competitive antagonist prepared in DMSO and left to stand at 30 °C for 60 minutes. Non-specific binding was determined as that remaining following incubation with 1  $\mu$ M MCH (Melanin concentrating hormone, H-1482 Bachem). The reaction was  
15 terminated by transfer of the reaction to GF/A filters using a Micro96 Harvester (Skatron Instruments, Norway). Filters were washed with assay buffer. Radioligand retained on the filters was quantified using a 1450 Microbeta TRILUX (Wallac, Finland).

Non-specific binding was subtracted from all values determined. Maximum binding was  
20 that determined in the absence of any competitor following subtraction of the value determined for non-specific binding. Binding of compounds at various concentrations was plotted according to the equation

$$y = A + ((B - A) / (1 + ((C/x)^D)))$$

and IC<sub>50</sub> estimated where

25 A is the bottom plateau of the curve i.e. the final minimum y value

B is the top of the plateau of the curve i.e. the final maximum y value

C is the x value at the middle of the curve. This represents the log EC50 value when A + B = 100

D is the slope factor. x is the original known x values. y is the original known y values.

30 The compounds exemplified herein had an IC<sub>50</sub> of less than 1  $\mu$ M in the abovementioned human MCHr binding assay. Preferred compounds had an activity of less than 0.3  $\mu$ M. For

instance, the following  $IC_{50}$  values were obtained for the compounds of the following examples:

Example 3, 0.167  $\mu$ M

Example 8, 0.105  $\mu$ M

5 Example 29, 0.066  $\mu$ M

Assays may also be performed on membranes prepared from HEK293 cells stably expressing the rat Melanin concentrating hormone receptor 1 (MCH1r) (Lembo et al. *Nature Cell Biol.* 1 267-271). Assays were performed in a 96-well plate format in a final  
10 reaction volume of 200  $\mu$ l per well. Each well contained 5  $\mu$ g of membrane proteins diluted in binding buffer (50 mM Tris, 3 mM  $MgCl_2$ , 0.05 % bovine serum albumin and the radioligand  $^{125}I$ -MCH (IM344 Amersham) was added to give 10 000 cpm (counts per minute) per well. Each well contained 2  $\mu$ l of the appropriate concentration of competitive  
15 antagonist prepared in DMSO and left to stand at room temperature for 60 minutes. Non-specific binding was determined as that remaining following incubation with 1  $\mu$ M MCH (Melanin concentrating hormone, H-1482 Bachem). The reaction was terminated by transfer of the reaction to GF/A filters using a Micro96 Harvester (Skatron Instruments, Norway). Filters were washed with assay buffer. Radioligand retained on the filters was quantified using a1450 Microbeta TRILUX (Wallac, Finland).

20

#### MCH1 functional assay

Membranes expressing recombinant hMCHr (5.45 pmol/mg protein; Euroscreen) were prepared in assay buffer (50 mM HEPES, 100 mM NaCl, 5 mM  $MgCl_2$ , 1 mM EDTA,  
25 200  $\mu$ M DTT, 20  $\mu$ M GDP (Sigma) containing 0.1  $\mu$ g/ml BSA, pH7.4) before assay. The assays were performed using membranes at 6  $\mu$ g/well in an assay volume of 200  $\mu$ l and the appropriate concentrations of compounds prepared in DMSO. The reaction was started by addition of 0.056 nM [ $^{35}S$ ]GTP $\gamma$ S (Specific activity >1000 Ci/mmol; Amersham) and an  $ED_{80}$  concentration of MCH (determined for each membrane and each MCH batch). Non-  
30 specific binding was determined using 20  $\mu$ M non-radiolabelled GTP $\gamma$ S. Plates were incubated for 45 min at 30°C. Free and bound GTP $\gamma$ S were separated by filtration binding

using GF/B filter mats presoaked in wash buffer (50 mM Tris, 5 mM MgCl<sub>2</sub>, 50 mM NaCl, pH 7.4) using a Micro96 cell harvester (Skatron Instruments) and the filters then dried at 50°C before counting using a1450 Microbeta TRILUX (Wallac).

- 5 Data are means  $\pm$  SD for experiments performed in triplicate. IC<sub>50</sub> values of antagonists were determined using non-linear regression analysis of concentration response curves using Activity Base. For instance, the following IC<sub>50</sub> values were obtained for the compounds of the following examples:

Example 3, 0.045  $\mu$ M

10 Example 8, 0.111  $\mu$ M

Example 29, 0.066  $\mu$ M

#### Pharmacodynamic effect in rat

Male Wistar-Hanover rats (Charles River, 300-350 grams) were acclimated to individually  
15 housing in conventional cages (Makrolon III) with 12:12 hour light-dark photoperiod (lights on at 06.00) in a temperature (20-22°C) and humidity (40-60%) controlled room. R-3 lab chow (Lactanin, Vadstena, Sweden) and tap water from bottles were allowed ad libidum. At 16.00 on the day before experiments, animals were weighed & food (but not water) was removed. At 08.00 on experiment day, animals were weighed & compound  
20 (i.p. amorphous nanoparticle formulation, 5ml/kg) or vehicle (3-10% DMA depending on compound formulation) administered. Animals were returned to their home cages & given access to a weighed amount of food. This food was then re-weighed 1, 2, 4, 6 & 24 hours later, and food consumption calculated by the difference from initial food weight. For example, the compound of Example 34 (16.7  $\mu$ mol/kg) reduced food intake by 20 %  
25 during the time interval 0-4 h.

Animals were further weighed at the 24-hr timepoint, and change in body weight over the treatment period was calculated. Compounds of the invention significantly decreased weight gain over the 24-hr observation period.


Pharmacodynamic effect in mouse

Female C57Bl6 mice (19-21 g) were singly housed for 7-days with *ad libitum* access to a "bland-paste" made from normal laboratory chow (R-3 Lactanin, Vadstena, Sweden) or to a "palatable-paste" of similar consistency containing oatmeal, butter, sugar, cocoa powder, cocoa butter & peanut butter. The day before the experimental day, food was removed for 12 hours. At 09.00 on experiment day, animals were weighed & compound (i.p. amorphous nanoparticle formulation, 10 ml/kg) or vehicle (0.1% Tween 80 or <5% DMA, depending on compound formulation) administered. Animals were returned to their home cages & given access to weighed amounts of both bland & palatable pastes. This food was then re-weighed 2, 4 and 6 hours later, and consumption of each food type calculated by the difference from initial food weight. Animals were further weighed at 24-hrs after administration, and change in body weight over the treatment period was calculated.

Compounds of the invention gave a significant decrease in food intake, the effect being more pronounced on the reduction of intake of "palatable-paste" food. Compounds of the invention also significantly decreased weight gain over the 24-hr observation period.

### Claims

1. A compound of formula I



(I)

wherein X represents a 5-10 membered aryl or heteroaryl ring, such as phenyl or naphthyl, or a heterocyclic group selected from pyrrolyl, imidazolyl, furyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrazolyl, oxazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinolinyl, isoquinolyl, quinazolyl, indolyl, benzofuranyl, benzo[b]thienyl or benzimidazolyl,

wherein each X is optionally substituted by one or more of the following: cyano, halo, a C<sub>1-4</sub> alkyl group optionally substituted by one or more fluoro, a C<sub>1-4</sub> alkoxy group optionally substituted by one or more fluoro, a group CONR<sup>a</sup>R<sup>b</sup> in which R<sup>a</sup> and R<sup>b</sup> independently represent a C<sub>1-3</sub> alkyl group, phenyl, phenoxy, 2-pyridyl or 3-pyridyl, wherein the aromatic substituents (i.e. phenyl, phenoxy, 2-pyridyl or 3-pyridyl) may optionally be substituted by fluoro, chloro or cyano,

Y can be OCH<sub>2</sub>, SCH<sub>2</sub> (both in which the heteroatom is connected to X), CH<sub>2</sub>CH<sub>2</sub> or CH=CH, wherein each carbon in Y can be substituted by 1-2 methyl groups and/or 1-2 fluoro,

R<sup>1</sup> represents H or a C<sub>1-4</sub>alkyl group,

Z represents phenyl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, isoxazolyl wherein each Z is optionally substituted by one or more of the following: cyano, halo, a C<sub>1-4</sub> alkyl group optionally substituted by one or more fluoro, a C<sub>1-4</sub> alkoxy group optionally substituted by one or more fluoro,

W represents phenyl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, isoxazolyl wherein each W is optionally substituted by

one or more of the following: cyano, halo, a C<sub>1-4</sub> alkyl group optionally substituted by one or more fluoro, a C<sub>1-4</sub> alkoxy group optionally substituted by one or more fluoro, as well as tautomers, optical isomers and racemates thereof as well as pharmaceutically acceptable salts thereof,

5 with the proviso that 2-(4-chlorophenoxy)-N-{1-[4-(1,2,3-thiadiazol-4-yl)benzyl]piperidin-4-yl}acetamide is excluded.

2. A compound according to claim 1, in which X represents a phenyl or pyridyl group substituted with one or more cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl,

10 Y is OCH<sub>2</sub> or SCH<sub>2</sub> (both in which the heteroatom is connected to X) CH<sub>2</sub>CH<sub>2</sub> or CH=CH, R<sup>1</sup> is hydrogen or methyl,

Z is phenyl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrrolyl wherein each Z is optionally substituted by cyano, fluoro, chloro or trifluoromethyl,

15 W represents phenyl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, isoxazolyl wherein each W is optionally substituted by one or more of the following: cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl,

20 as well as pharmaceutically acceptable salts, thereof.

3. A compound according to claim 1 or claim 2, wherein X represents naphthyl or a heteroaryl ring selected from quinolinyl, isoquinolyl, quinazolyl, indolyl, benzofuranyl, benzo[b]thienyl, or benzimidazolyl,

25 wherein each X is optionally substituted by one or more of the following: cyano, halo, a C<sub>1-4</sub> alkyl group optionally substituted by one or more fluoro, a C<sub>1-4</sub> alkoxy group optionally substituted by one or more fluoro, a group CONR<sup>a</sup>R<sup>b</sup> in which R<sup>a</sup> and R<sup>b</sup> independently represent a C<sub>1-3</sub> alkyl group,

Y is OCH<sub>2</sub> or SCH<sub>2</sub> (both in which the heteroatom is connected to X) CH<sub>2</sub>CH<sub>2</sub> or CH=CH,

30 R<sup>1</sup> is hydrogen or methyl,

Z is phenyl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrrolyl wherein each Z is optionally substituted by cyano, fluoro, chloro or trifluoromethyl,



W represents phenyl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, isoxazolyl wherein each W is optionally substituted by one or more of the following: cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl,  
5 as well as pharmaceutically acceptable salts, thereof.

4. A compound according to any of the preceding claims, wherein X represents phenyl or pyridyl group optionally substituted by one or more halogen and is further substituted by a  
10 phenyl, phenoxy, 2-pyridyl or 3-pyridyl group, wherein the substituents (*i.e.* phenyl, phenoxy, 2-pyridyl or 3-pyridyl) may optionally be further substituted by one or more fluoro, chloro or cyano,

Y is  $\text{OCH}_2$  or  $\text{SCH}_2$  (both in which the heteroatom is connected to X)  $\text{CH}_2\text{CH}_2$  or  $\text{CH}=\text{CH}$ ,  
 $\text{R}^1$  is hydrogen or methyl,

15 Z is phenyl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrrolyl wherein each Z is optionally substituted by cyano, fluoro, chloro or trifluoromethyl,

W represents phenyl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, isoxazolyl wherein each W is optionally substituted by  
20 one or more of the following: cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl,  
as well as pharmaceutically acceptable salts, thereof.

5. A compound according to any of the preceding claims, in which X represents a phenyl  
25 group substituted with one or more cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl,

Y is  $\text{OCH}_2$  (in which the heteroatom is connected to X),

$\text{R}^1$  is hydrogen,

Z is thienyl, furyl or pyrrolyl,

30 W represents phenyl or a heterocyclic group selected from pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl,

isoxazolyl wherein each W is optionally substituted by one or more of the following: cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl, as well as pharmaceutically acceptable salts thereof.

- 5 6. A compound according to any of the preceding claims, in which X represents a phenyl group substituted with one or more cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl,  
Y is  $\text{OCH}_2$  (in which the heteroatom is connected to X),  
 $\text{R}^1$  is hydrogen,  
10 Z is 2,5-thienyl (where position 1 is linked to group W),  
W represents phenyl or a heterocyclic group selected from pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, isoxazolyl wherein each W is optionally substituted by one or more of the following: cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl,  
15 as well as pharmaceutically acceptable salts thereof.

7. A compound according to any of the preceding claims, in which X represents a phenyl group substituted with one or more cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl,  
20 Y is  $\text{OCH}_2$  (in which the heteroatom is connected to X),  
 $\text{R}^1$  is hydrogen,  
Z is 2,5-furyl (where position 1 is linked to group W),  
W represents phenyl or a heterocyclic group selected from pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl,  
25 isoxazolyl wherein each W is optionally substituted by one or more of the following: cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl,  
as well as pharmaceutically acceptable salts thereof.

8. A compound according to any of the preceding claims, in which X represents a phenyl group substituted with one or more cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl,  
30 Y is  $\text{OCH}_2$  (in which the heteroatom is connected to X),

R<sup>1</sup> is hydrogen,

Z is 1,3-1*H* pyrrolyl (in which the heteroatom is connected to W),

W represents phenyl or a heterocyclic group selected from pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, isoxazolyl wherein each W is optionally substituted by one or more of the following: cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl, as well as pharmaceutically acceptable salts thereof.

9. A compound according to any of the preceding claims, in which Z is pyrrolyl.

10. A compound according to any of the preceding claims, in which Z is 1,3-1*H* pyrrolyl (in which the heteroatom is connected to W).

11. A compound according to any of the preceding claims, in which W is phenyl or 2-pyridyl, optionally substituted by one or more of the following: cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl.

12. A compound according to any of the preceding claims, in which Y is OCH<sub>2</sub>.

13. One or more of the following compounds:

2-(3-chlorophenoxy)-*N*-[1-[(1-phenyl-1*H*-pyrrol-3-yl)methyl]piperidin-4-yl]acetamide

2-(3-chlorophenoxy)-*N*-[1-[(1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl)methyl]piperidin-4-yl]acetamide

2-(3-chlorophenoxy)-*N*-(1-[[1-(4-methoxyphenyl)-1*H*-pyrrol-3-yl)methyl]piperidin-4-yl)acetamide

2-(3-chlorophenoxy)-*N*-(1-[[1-(2-chlorophenyl)-1*H*-pyrrol-3-yl)methyl]piperidin-4-yl)acetamide

2-(3-chlorophenoxy)-*N*-[1-[(1-[5-(trifluoromethyl)pyridin-2-yl]-1*H*-pyrrol-3-yl)methyl]piperidin-4-yl]acetamide

2-(3-chlorophenoxy)-*N*-(1-([1-(3-chlorophenyl)-1*H*-pyrrol-3-yl)methyl]piperidin-4-yl)acetamide

2-(3-chlorophenoxy)-*N*-[1-(4-pyridin-2-ylbenzyl)piperidin-4-yl]acetamide

2-(3-chlorophenoxy)-*N*-(1-([5-(4-chlorophenyl)-2-furyl]methyl)piperidin-4-yl)acetamide

5 2-(3-chlorophenoxy)-*N*-[1-([1-(4-(trifluoromethoxy)phenyl)-1*H*-pyrrol-3-yl)methyl]piperidin-4-yl]acetamide

2-(3-chlorophenoxy)-*N*-[1-(3-(1*H*-pyrrol-1-yl)benzyl)piperidin-4-yl]acetamide

2-(3-chlorophenoxy)-*N*-[1-(3-pyridin-2-ylbenzyl)piperidin-4-yl]acetamide

2-(3-chlorophenoxy)-*N*-(1-([5-(2,4-dichlorophenyl)-2-furyl]methyl)piperidin-4-yl)acetamide

2-(3-chlorophenoxy)-*N*-[1-([5-[1-methyl-5-(trifluoromethyl)-1*H*-pyrazol-3-yl]-2-thienyl]methyl)piperidin-4-yl]acetamide

*N*-(1-([1-(4-bromophenyl)-1*H*-pyrrol-3-yl)methyl]piperidin-4-yl)-2-(3-chlorophenoxy)acetamide

15 2-(3-chlorophenoxy)-*N*-methyl-*N*-[1-([1-(4-(trifluoromethyl)phenyl)-1*H*-pyrrol-3-yl)methyl]piperidin-4-yl]acetamide

2-[(3-chlorophenyl)thio]-*N*-[1-([1-(4-(trifluoromethyl)phenyl)-1*H*-pyrrol-3-yl)methyl]piperidin-4-yl]acetamide

2-(pyridin-3-yloxy)-*N*-[1-([1-(4-(trifluoromethyl)phenyl)-1*H*-pyrrol-3-yl)methyl]piperidin-4-yl]acetamide

2-[3-(trifluoromethoxy)phenoxy]-*N*-[1-([1-(4-(trifluoromethyl)phenyl)-1*H*-pyrrol-3-yl)methyl]piperidin-4-yl]acetamide

2-[3-(trifluoromethoxy)phenoxy]-*N*-[1-([1-(5-(trifluoromethyl)pyridin-2-yl)-1*H*-pyrrol-3-yl)methyl]piperidin-4-yl]acetamide

25 2-(3-cyanophenoxy)-*N*-[1-([1-(4-(trifluoromethyl)phenyl)-1*H*-pyrrol-3-yl)methyl]piperidin-4-yl]acetamide

2-(3-fluorophenoxy)-*N*-[1-([1-(4-(trifluoromethyl)phenyl)-1*H*-pyrrol-3-yl)methyl]piperidin-4-yl]acetamide

2-(3-cyanophenoxy)-N-[1-({5-[1-methyl-5-(trifluoromethyl)-1*H*-pyrazol-3-yl]-2-thienyl}methyl)piperidin-4-yl]acetamide

2-(2-chlorophenoxy)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide

5 2-(3-chlorophenoxy)-N-[1-({5-[4-(trifluoromethoxy)phenyl]-2-furyl}methyl)piperidin-4-yl]acetamide

2-(3-chlorophenoxy)-N-(1-({1-[4-(4-cyanophenyl)-1*H*-pyrrol-3-yl]methyl}piperidin-4-yl)acetamide

10 2-(3-cyanophenoxy)-N-(1-({5-(2,4-dichlorophenyl)-2-furyl}methyl}piperidin-4-yl)acetamide

2-(3-cyanophenoxy)-N-[1-({1-[4-(trifluoromethoxy)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide

2-(3-chlorophenoxy)-N-(1-({1-[5-chloropyrimidin-2-yl]-1*H*-pyrrol-3-yl]methyl}piperidin-4-yl)acetamide

15 3-(3-chlorophenyl)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]propanamide

(2*E*)-3-(3-chlorophenyl)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acrylamide

20 2-(3,5-difluorophenoxy)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide

2-(2,6-diisopropylphenoxy)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide

2-(3-isopropylphenoxy)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide

25 2-(2-cyanophenoxy)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide

2-(isoquinolin-5-yloxy)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide

and pharmaceutically acceptable salts thereof.

14. A compound of formula I as claimed in any one of claims 1 to 13 for use as a medicament.

15. A pharmaceutical formulation comprising a compound of formula I, as defined in any one of claims 1 to 13 and a pharmaceutically acceptable adjuvant, diluent or carrier.


16. Use of a compound of formula I including 2-(4-chlorophenoxy)-*N*-{1-[4-(1,2,3-thiadiazol-4-yl)benzyl]piperidin-4-yl}acetamide, as defined in any one of claims 1 to 13 in the preparation of a medicament for the treatment or prophylaxis of conditions associated with obesity.

17. A method of treating obesity, psychiatric disorders, anxiety, anxio-depressive disorders, depression, bipolar disorder, ADHD, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders and pain related disorders, comprising administering a pharmacologically effective amount of a compound as claimed in any one of claims 1 to 13 including 2-(4-chlorophenoxy)-*N*-{1-[4-(1,2,3-thiadiazol-4-yl)benzyl]piperidin-4-yl}acetamide to a patient in need thereof.

18. A method of treating obesity, type II diabetes, metabolic syndrome and prevention of type II diabetes comprising administering a pharmacologically effective amount of a compound as claimed in any one of claims 1 to 13 including 2-(4-chlorophenoxy)-*N*-{1-[4-(1,2,3-thiadiazol-4-yl)benzyl]piperidin-4-yl}acetamide to a patient in need thereof.


19. A compound as defined in any one of claims 1 to 13 including 2-(4-chlorophenoxy)-*N*-{1-[4-(1,2,3-thiadiazol-4-yl)benzyl]piperidin-4-yl}acetamide for use in the treatment of obesity.

20. A process for the preparation of compounds of formula I including 2-(4-chlorophenoxy)-*N*-{1-[4-(1,2,3-thiadiazol-4-yl)benzyl]piperidin-4-yl}acetamide comprising reacting a compound of formula II with a compound of formula III




in which X, Y, Z, W and R<sup>1</sup> are as previously defined,

21. A process for the preparation of compounds of formula I including 2-(4-chlorophenoxy)-N-{1-[4-(1,2,3-thiadiazol-4-yl)benzyl]piperidin-4-yl}acetamide comprising reacting a compound of formula IV with a compound of formula V



in which X, Q, L, Y, Z, W and R<sup>1</sup> are as previously defined,

22. A process for the preparation of compounds of formula I including 2-(4-chlorophenoxy)-N-{1-[4-(1,2,3-thiadiazol-4-yl)benzyl]piperidin-4-yl}acetamide comprising reacting a compound of formula VI with a compound of formula VII



in which X, Y, S, Z, W and R<sup>1</sup> are as previously defined,

23. The following compounds of formulae II, III, IV and VI, including salts thereof, which are useful as synthesis intermediates:

2-(3-chlorophenoxy)-N-piperidin-4-ylacetamide  
 2-(3-cyanophenoxy)-N-piperidin-4-ylacetamide  
 2-(3-fluorophenoxy)-N-piperidin-4-ylacetamide

- 2-(2-chlorophenoxy)-*N*-piperidin-4-ylacetamide  
*N*-piperidin-4-yl-2-(pyridin-3-yloxy)acetamide  
*N*-piperidin-4-yl-2-[3-(trifluoromethoxy)phenoxy]acetamide  
2-phenoxy-*N*-piperidin-4-ylacetamide  
5 2-(3-chlorophenoxy)-*N*-methyl-*N*-piperidin-4-ylacetamide  
2-[(3-chlorophenyl)thio]-*N*-piperidin-4-ylacetamide  
1-[5-(trifluoromethyl)pyridin-2-yl]-1*H*-pyrrole-3-carbaldehyde  
1-(5-chloropyrimidin-2-yl)-1*H*-pyrrole-3-carbaldehyde  
4-(3-formyl-1*H*-pyrrol-1-yl)benzonitrile  
10 2-chloro-*N*-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide  
1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-amine  
dihydrochloride  
*tert*-butyl[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]carbamate  
15



Abstract

Compounds of formula I, processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders and to pharmaceutical compositions containing them.

04001203